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Biogenic amine neurotransmitters are important modulators of the most basic functions 
of the central nervous system. The histaminergic system is one of the last biogenic 
amine systems to be discovered. Its neurons are located in a single nucleus of the 
hypothalamus, from where they send projections to almost all regions of the brain. 
Studies on the roles of the histaminergic system have revealed that it regulates many 
brain functions, such as motor functions, cognition, sleep, and brain plasticity and 
development. It has also been implicated to be involved in many neurological and 
psychiatric conditions, such as Parkinson’s disease, narcolepsy and alcoholism. 
Modulation of histamine signalling may thus provide an option for the treatment of 
these and other conditions. However, due to its relatively recent discovery, many 
unanswered questions about the histaminergic system remain. In this thesis, I studied 
the neuropharmacology of the histaminergic system using the zebrafish as a model of 
the vertebrate brain. 
In the first study, we analysed the effect of acute ethanol on the histaminergic and 
dopaminergic systems. The mRNAs of enzymes synthesizing dopamine and histamine 
were rapidly upregulated by a short ethanol exposure in a dose-dependent manner. 
Further immunohistochemical and in situ hybridization revealed that the number and 
localization of histaminergic and dopaminergic neurons was unaltered by ethanol 
treatment, suggesting that the transcriptional changes observed were localized to the 
cells that produce histamine and dopamine under normal conditions. When analysing 
neurotransmitter levels by HPLC, dopamine levels were decreased after a short 
treatment with ethanol but recovered to baseline levels during longer treatments, 
suggesting that the transcriptional changes observed represent a compensatory 
response. Interestingly, no significant changes were seen in histamine levels following 
ethanol treatment. Ethanol treatment resulted in a rapid and dose-dependent increase in 
locomotion of larvae, which declined over time with higher treatment doses. As the 
behavioural and transcriptional changes occurred within a similar time frame, our 
results suggest that histamine and dopamine may play a role in the locomotor effects of 
ethanol. 
In the second study, we showed that pharmacological inhibition of the vesicular 
monoamine transporter 2 (VMAT2) using reserpine depleted neural histamine from the 
brain, resulting in an almost total loss of histamine immunoreactivity in histaminergic 
fibres and a decreased number of histamine immunoreactive neurons. These results 
were supported by decreased levels of histamine and other amine neurotransmitters. 
Interestingly, depletion of histamine did not result in the upregulation of its synthesis, 
although enzymes synthesizing the other aminergic transmitters were significantly 
upregulated after VMAT2 inhibition. Behaviourally, VMAT2 inhibition resulted in a 
decreased dark-induced flash response of zebrafish larvae, a brief spike in locomotor 
activity during the first second of sudden onset of darkness, which has been described 
as histamine dependent. However, aside from the dark-flash response, reserpine-treated 
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larvae showed an increased hypermotor response to sudden darkness, which suggests 
that monoaminergic transmission regulates darkness adaptation of zebrafish. 
In the third study, we characterized the expression of the zebrafish histamine receptor 
hrh3 and generated a hrh3 knockout strain using the CRISPR-Cas9 method of targeted 
genome editing. Expression of hrh3 was most prominent in the pallium of the 
telencephalon, the region containing higher centers of zebrafish brain function, 
functionally analogous to the mammalian cortex, amygdala and hippocampus. Double 
fluorescent in situ hybridization revealed that the majority of hrh3 expressing neurons 
in the telencephalon were glutamatergic, suggesting that hrh3 regulates glutamatergic 
neurotransmission in the zebrafish. This is some of the only direct molecular evidence 
of the transmitter phenotype of hrh3-expressing cells. In our knockout model, we saw 
that hrh3 knockout larval zebrafish adapted faster to sudden onset of darkness, 
indicating that hrh3 can regulate adaptation to sudden changes in the environment of 
the zebrafish. Although basic behavioural parameters of hrh3 knockout larvae were 
unaltered, adult hrh3 knockout fish showed decreased locomotor activity, suggesting 
that hrh3 signalling may have different functional roles at different ages. 
Neurochemically, zebrafish larvae had decreased levels of dopamine and serotonin, 
supporting previous findings that hrh3 is involved in the regulation of these systems. 
We saw no changes in the expression of genes relevant to aminergic neurotransmission 
or the organisation of the aminergic networks, suggesting that the altered 
neurotransmitter levels reflect functional changes in otherwise intact networks. 
In total, these results provide some new answers to open questions in the field of 
histamine neuropharmacology, specifically concerning the effects of alcohol on the 
histaminergic system and the mechanisms of vesicular storage of histamine. 
Additionally, we provide the first thorough characterization of a histamine receptor 
knockout model in a diurnal vertebrate, the zebrafish. In concordance with previous 
studies in rodents, we found that hrh3 knockout results in relatively modest phenotypes 
and might be relevant in the adaptation to sudden changes in the environment. Also, we 
provided further evidence of the role of hrh3 in the regulation of other aminergic 
networks, i.e. the serotonergic and dopaminergic systems. We also noted that hrh3 is 
particularly strongly expressed in glutamatergic cells of the telencephalon, suggesting 
that the role of hrh3 in the modulation of glutamatergic transmission and its functional 





The vertebrate brain is the most complex organ, consisting of a complex network of 
neurons that are connected to each other by synapses. It forms the basis of our 
consciousness, being responsible for interpretation of sensory information from our 
surroundings and for execution of behaviour. The complex and robust signalling 
between neurons required for these functions is made possible by neurotransmitters, 
small endogenous molecules that are released by neurons in synapses. Released 
neurotransmitters bind to receptors on the postsynaptic neuron, thus altering its 
membrane potential, excitability or firing rate. Given the importance of 
neurotransmitters, identification of the function of specific transmitter molecules and 
their receptors in the healthy and pathological brain has provided the foundation for 
modern neuropharmacology. 
 Of the different neurotransmitter classes, the biogenic amine 
transmitters dopamine, serotonin and noradrenaline have attracted particular 
neuropharmacological interest for their importance in many neurological and 
psychiatric conditions. This has been the result of intensive research into the structural 
organisation and receptor properties of these transmitter networks both in experimental 
animals and clinical settings, which has led to successful drug development. For 
instance, drugs that potentiate dopaminergic transmission form the cornerstone of 
pharmacological treatment of motor disorders such as Parkinson’s disease, and 
serotonin and noradrenaline reuptake inhibitors are widely used in the treatment of 
depression. 
 Histamine is one of the last biogenic amine neurotransmitters to be 
discovered. It has been implicated to be of importance in the regulation of motor 
functions, the neurobiology of alcoholism, many psychiatric disorders and cognitive 
functions, for instance. In many of the previous studies, histamine has been 
characterized as having primarily a modulatory role, adjusting transmitter release and 
signalling of other networks. However, the neurobiology of histamine has attracted 
considerably less research attention than other neurotransmitter systems, and many key 
questions about fundamental properties of the histamine neurons and histamine 
receptors still remain to be properly investigated. Further research into the 
histaminergic system is thus warranted, and a better understanding of the 
pharmacology of histamine in the brain could potentially lead to the development of 
new treatment options for neurological and psychiatric diseases. 
 In this thesis, I have studied the pharmacology, neuroanatomy and 
molecular properties of histamine and its receptor Hrh3 using the zebrafish as a model 
of the vertebrate brain, in comparison to the other aminergic neurotransmitter 
networks. I present novel findings concerning the effects of alcohol on the 
histaminergic and dopaminergic systems, the mechanism of vesicular storage of 
histamine and the molecular and behavioural changes following monoamine depletion. 
Additionally, I describe the phenotype of a zebrafish Hrh3 knockout animal. Taken 
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2. Review of the Literature 
 
2.1 The histaminergic neurotransmitter system in the vertebrate brain 
 
2.1.1 Histaminergic neurons and their projections 
The physiological properties of histamine were first described in 1910 by Dale and 
Laidlaw, who initially characterized histamine as a strong vasodilator and constrictor 
of bronchial and other smooth muscle tissue 1. Histamine was soon thereafter identified 
as a mediator of inflammation 2,3 and gastric acid secretion 4. The research and 
pharmacological interest in histamine was for a long time concerned merely with these 
peripheral effects 5. 
Kwiatkowski, who in 1943 discovered histamine in homogenates of brain and nerves 
of different mammalian species, was first to suggest that histamine acts as a 
neurotransmitter 6. Further studies revealed that histamine from brain extracts was 
localized in the same subcellular fraction as synaptosomes containing noradrenaline 
and serotonin, suggesting that brain histamine might be localized in neurons 7. 
Mammalian histamine and histidine decarboxylase (HDC) -containing neuronal cell 
bodies were first identified in the rat, located exclusively in the tuberomammillary 
nucleus of the posterior hypothalamus 8,9. Although no histamine or HDC containing 
neuronal soma were seen in other parts of the brain, these studies found extensive 
histamine and HDC containing fibres in many brain regions, such as the cortex, 
hippocampus, amygdala, basal ganglia, hypothalamus and many brainstem regions. 
This organization is similar to that observed in other aminergic neurotransmitter 
systems, such as the noradrenergic and dopaminergic systems – the aminergic neuronal 
cell bodies are localized in one or a few distinct regions, but they project extensively to 
many different brain regions 10-14. Later studies showed that the organization of the 
histaminergic network is similar in humans 15, other mammalian models 16-18, 
amphibians 19 and fish 20, indicating that this neurotransmitter system is well conserved 
in vertebrates. The wide distribution in the brain suggested a modulatory role of 
histamine in brain functions. After its discovery, histamine has been implicated in 
many key functions of the brain, as shall be described later in this review. 
 
2.1.2 The biosynthesis of neural histamine and its regulation 
Histamine in vertebrates is synthesized from the essential amino-acid L-histidine in a 
single step decarboxylation reaction catalysed by HDC 21. Neural uptake of L-histidine 
does not seem to be an important point of regulation in histamine synthesis, as histidine 
uptake into neurons is independent of changes in the neuronal membrane potential 22,23. 
However, it should be noted that substrate availability seems to be essential in the 
synthesis of histamine in the brain, as the activity of HDC is not saturated with 
physiological concentrations of L-histidine in the mammalian brain, although the 
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relevance of this mechanism is poorly understood 24. The synthesis of histamine is also 
regulated through the activity of HDC. Phosphorylation by the cyclic adenosine 
monophosphate (cAMP) dependent protein kinase A (PKA) increases histamine 
synthesis, suggesting that HDC is positively regulated by phosphorylation 25. Another 
phosphorylation pathway, mediated by the calcium-calmodulin dependent protein 
kinase II (CaMKII) also stimulates histamine synthesis and increases HDC activity 26. 
As would be expected by these results, protein phosphatases regulate HDC activity 
negatively 27. Post-translational modifications thus play a key role in the regulation of 
HDC activity. However, the role of HDC synthesis in the regulation of histamine 
metabolism is poorly studied and understood. In the gut, gastrin and the pituitary 
adenylate cyclase-activating peptide (PACAP) are known to increase HDC mRNA 
synthesis 28, but this effect has not yet been described in the brain. Several regulatory 
elements were identified in proximity to the gene coding for human HDC 29. This 
suggests that regulation of histamine synthesis by HDC could also occur at a 
transcriptional level, but it is currently unknown what signalling pathways or biological 
conditions would cause this in the brain. 
 
2.1.3 Storage of histamine in neurons 
Immunohistochemical data support the conclusion that histamine is stored in vesicle-
like structures, comparable to other aminergic transmitters 30. Histamine, like the 
catecholamines and serotonin, is a substrate of VMAT2 31, which is also expressed in 
histaminergic neurons 31. However, the role of VMAT2 in histamine metabolism in the 
brain is partially unclear. When the function of VMAT2 is inhibited by the indole 
alkaloid reserpine, the storage of catecholamines and serotonin is inhibited, leading to 
the subsequent metabolism of these transmitters and a dramatic decrease of their 
measured concentrations in the brain 32. Results with histamine have been unclear and 
contradictory, with some studies indicating that reserpine lowers brain histamine levels 
33,34, while other studies point to unchanged histamine levels following reserpine 
treatment 35,36. Interpretation of many of these studies is further complicated by the 
presence of histamine in mast cells in the brain 8,9. Further studies are thus needed to 
conclusively demonstrate the relationship between neural histamine and VMAT2. 
 
2.1.4 Reuptake and metabolism of histamine in the brain 
All the other monoamines in the brain – dopamine, serotonin and noradrenaline – have 
specific reuptake transporters that terminate the action of the transmitter in the synaptic 
cleft after release and that are expressed on neurons or glia 37. In the case of histamine, 
no such transporters have been described. Instead, histamine has been shown to be 
transported by several nonspecific cell membrane transporters – the organic cation 
transporters (OCT) 2 and 3 38,39 and the plasma membrane monoamine transporter 
(PMAT) 40. OCT3 and PMAT are expressed in astrocytes and transport histamine in 
vitro, with PMAT being the major transporter and OCT3 playing a more minor role 41. 
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This transport is likely to be functionally relevant, as toxic inhibition of astrocyte 
function increases histamine levels 42. Astrocytes also express histamine n-
methyltransferase (HNMT), the cytosolic enzyme responsible for metabolizing 
histamine into n-methylhistamine 41. It is thus likely that extracellular histamine (i.e. 
from the synaptic cleft after transmitter release) is taken into astrocytes for enzymatic 
degradation. However, there is also evidence of neuronal reuptake of histamine 43 and 
neural expression of HNMT, suggesting that neurons might also partake in the 
reuptake and metabolism of histamine 44,45. It should be noted that although histamine 
can also be metabolized by diamine oxidase (DAO), activity of this enzyme is minimal 
in the brain 46. 
 
2.1.5 Histamine receptors 
In vertebrates, four different types of histamine receptors have been described (HRH1, 
HRH2, HRH3 and HRH4) 47. All of these are metabotropic GPCRs (G-protein-coupled 
receptors) – there is also evidence of histamine action on certain types of GABAA 
channels, but the in vivo relevance of this remains unknown 48. Additionally, histamine 
also seems to potentiate the current of N-methyl-D-aspartate receptors by binding to 
the polyamine binding site on this receptor, thus reinforcing the action of glutamate at 
this receptor 49,50. Here, the basic signalling properties and brain locations of the 
different histamine receptors are briefly described; their role in specific brain functions 
will be discussed later. 
 
2.1.5.1 Receptor abbreviation nomenclature 
In the literature, several different abbreviations and symbols have been used to refer to 
the histaminergic receptors. In this thesis, the abbreviations and symbols recommended 
by the International Union of Basic and Clinical Pharmacology are used 51.   
 
2.1.5.2 Histamine receptor HRH1 
HRH1 is linked to the Gq/11 class of G-proteins 52. Activation of the receptor thus leads 
to the activation of phospholipase C, which produces the secondary messengers diacyl 
glycerol (DAG) and inositol trisphosphate (IP3) , leading to the activation of protein 
kinase C and release of calcium from the endoplasmic reticulum, respectively 53. 
HRH1 is also linked to several other signalling pathways through stimulation of the 
production of arachidonic acid and nitric oxide 54. 
HRH1 is expressed widely in the central nervous system. As well as in neurons, it is 
also found in astrocytes 55, brain endothelium 56 and cells of the immune system 
circulating in the brain 57. Thus, not all HRH1 mediated effects on brain function are 
caused by neurotransmission, but might also result from modulation of glial, vascular 
and inflammatory functions in the brain. Neural HRH1 is present postsynaptically in 
many brain regions, such as the cerebral cortex, the limbic system, thalamus, 
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hippocampus, basal ganglia and cerebellum. In most of these areas, HRH1 signalling is 
excitatory, although inhibitory signalling has been reported in the hippocampus 54,58,59. 
HRH1 also displays constitutive activity – active signalling even in the absence of a 
ligand, a property occasionally seen in GPCRs 60,61.  
 
2.1.5.3 Histamine receptor HRH2 
HRH2 is linked to the mainly excitatory Gs class of G-proteins, and acts through 
stimulation of adenylate cyclase and production of cAMP, which further leads to the 
activation of protein kinase A and the transcriptional regulator CREB 54. This 
signalling pathway is implicated especially in neural plasticity and development, and 
has also been suggested as being linked to the pathogenesis of neurodegenerative 
diseases 62,63. Like HRH1, HRH2 displays constitutive signalling activity 64,65, 
suggesting that HRH2 might be important in maintaining a baseline activity of protein 
kinase A and CREB in neurons, although the relevance of this has not been studied. 
HRH2 has a widespread expression in the brain, being present in neurons, astrocytes, 
endothelium and leukocytes 54,56,57. Although HRH2 and HRH1 are expressed in the 
same brain regions (such as the cortex and limbic system), their expression patterns 
within these regions differ, suggesting that the receptors have different target cells 
54,66,67. 
 
2.1.5.4 Histamine receptor HRH3 
Signalling by HRH3 is highly complex. It is linked to the inhibitory Gi/o class of G-
proteins, inhibiting adenylate cyclase function and thus decreasing production of 
adenylate cyclase 68. Gi/o also directly inhibits voltage-gated calcium channels 69. 
Furthermore, HRH3 activation is positively coupled to the mitogen-activated protein 
kinase (MAPK) 70 and Akt signalling pathways 71, both of which are relevant in brain 
plasticity and development. Action of HRH3 on neurons is mainly inhibitory, although 
the multiple downstream signalling pathways of the receptor make this distinction 
unclear 72. HRH3 also displays an unusual multitude of functional isoforms, resulting 
from alternative splicing processes, with different isoforms displaying differences in 
signalling properties and ligand responses 70,73,74. Although both HRH1 and HRH2 
display constitutive signalling activity, HRH3 has an exceptionally high constitutive 
activity 75, with most HRH3 antagonists actually acting as inverse agonists, decreasing 
basal signalling 58. The high constitutive activity enables HRH3 to have functional 
significance regardless of the presence of histamine. For instance, HRH3 antagonists 
have been shown to have neuroprotective effects even in animals lacking histamine 76. 
In contrast to the other histamine receptors, HRH3 was long believed to be expressed 
primarily in histaminergic neurons in the brain, where HRH3 was first identified as an 
autoreceptor on histaminergic neurons regulating histamine release 77. Later, HRH3 
was shown to act as a presynaptic receptor regulating the release of many other 
neurotransmitters 78-81, supported by HRH3 ligand binding and mRNA expression often 
being localized at different sites 82. Similarly as HRH1 and HRH2, HRH3 expression is 
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found in many key regions of the brain 54. HRH3 was also relatively recently described 
as a postsynaptic receptor in the basal ganglia, where it forms heterodimers with 
dopamine receptors DRD1 and DRD2, thus modulating dopaminergic signalling 83. 
However, the exact transmitter phenotype of neurons expressing HRH3 remains 
unknown in most brain regions. 
Although initially believed to be restricted to neurons, HRH3 expression was recently 
also found in astrocytes 55. As other histamine receptors, HRH3 is expressed in the 
brain endothelium 84. However, it has so far not been found in brain leukocytes 58. 
 
2.1.5.5 Histamine receptor HRH4 
Like HRH3, HRH4 is also linked to Gi/o, acting through inhibition of the adenylate 
cyclase – cAMP pathway 85. Currently, involvement in other signalling pathways has 
not been described. So far, there is insufficient proof of HRH4 expression in the 
neurons of the central nervous system, although HRH4 has been detected in peripheral 
neurons 86. HRH4 is, however, expressed in leukocytes 57 and endothelial 84 cells in the 
brain, and HRH4 signalling might be relevant in brain function through this 
mechanism. 
 
2.1.6 Cotransmitters and non-histamine mediated effects of histaminergic neurons 
Aminergic neurons often co-release other neurotransmitters, such as the small 
molecule transmitters glutamate or GABA 87,88. Histaminergic neurons in mammals 
also coexpress several other transmitters, most notably GABA, which has been found 
in a majority of histaminergic neurons 89. The role of these cotransmitters in the 
function of the histaminergic network is poorly understood. A recent study identified 
that inhibition of GABA release in histaminergic neurons of mice increased their 
activity, suggesting that GABA limits and modulates the effects of released histamine 
90. Thus, not all functions of the histaminergic neurons involve histamine, which should 
be taken into account when studying the role of histamine in the brain. 
 
2.2 Overview of the other biogenic amine neurotransmitter systems in the 
brain 
 
Modulation of other biogenic amine systems in the brain seems to be a key role of the 
histaminergic system, as shall be reviewed in chapter 2.3. Thus, it is necessary to 
briefly present the organization of these systems in the brain. The biogenic amine 
neurotransmitter systems were first described by Dahlström and Fuxe in 1964 13, and 
have since been extensively studied in different species. Figure 1 provides an overview 




2.2.1 The dopaminergic system 
Dopamine, previously also known as 3-hydroxytyramine, was initially believed to be 
merely an intermediate product in the synthesis of noradrenaline. It was first suggested 
as acting as a neurotransmitter in 1957, when Dr. A. Carlsson and colleagues described 
substantial amounts of dopamine in the striatum 91.  Dopamine is synthesized in a two-
step reaction from the amino acid L-tyrosine. First, L-tyrosine is converted into L-
DOPA (3,4-dihydroxyphenylalanine) by the enzyme tyrosine hydroxylase (TH) 92. This 
is the rate-limiting step in dopamine biosynthesis, and both transcriptional and 
phosphorylation-based post-translational mechanisms for the regulation of dopamine 
biosynthesis have been described at this step 93,94. L-DOPA is further converted into 
dopamine by aromatic L-amino acid decarboxylase (AADC) 95. In the brain, 
synthesized dopamine is loaded into vesicles by VMAT2 96. Dopamine released into 
the synaptic cleft is cleared by a high-affinity reuptake mechanism through the 
dopamine transporter (DAT), although in some brain regions, dopamine can also be 
removed by the noradrenaline transporter (NET) 97. Dopamine is metabolized by two 
main pathways – through oxidative deamination by the enzyme monoamine oxidase 
(MAO) into dihydroxyphenylacetic acid (DOPAC), and through O-methylation by 
catechol-O-methyltransferase (COMT) into 3-methoxytyramine (3-MT) 98. In general, 
MAO is more abundantly present in neurons, while COMT is more prominent in 
peripheral organs and in glial cells 98. The action of dopamine is mediated by at least 
five different types of metabotropic GPCRs, all of which are expressed in the brain 99. 
In mammals and other vertebrates, dopaminergic neurons in the brain are found in 
populations A8-A17 of catecholaminergic cells, which are located in the midbrain (A8-
A10), diencephalon (A11-A15), olfactory bulb (A16) and retina (A17), although 
individual dopaminergic cells have also been described in other regions 100. Dopamine 
is involved in many key functions of the brain. For instance, the nigrostriatal 
dopaminergic system (consisting of projections from population A9) is pivotal in the 
regulation of voluntary motion and other motor functions 101 and the mesolimbic 
pathway (A10) is involved in the perception of rewarding stimuli and the pathogenesis 
of addiction and abuse of intoxicating substances such as ethanol 102,103. 
2.2.2 The noradrenergic system 
Noradrenaline was one of the first neurotransmitters to be discovered, initially 
described as the transmitter of the sympathetic nervous system 104. Noradrenaline is 
synthesized from dopamine in a single step through beta-hydroxylation by dopamine 
beta-hydroxylase (DBH)105. In contrast to other monoamine transmitters, noradrenaline 
is synthesized inside synaptic vesicles. Noradrenergic transmission can thus be 
considered to be VMAT2 dependent, as functional VMAT2 is required for dopamine 
to be available in the vesicles for synthesis. Released noradrenaline is transported back 
into the presynaptic terminal by the noradrenaline transporter (NET) 37, and neural 
noradrenaline is degraded primarily through the action of MAO 106. Noradrenaline acts 
through α and β adrenergic receptors, both of which are expressed in the brain 107. 
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The majority of noradrenergic neurons in vertebrates are located in the sympathetic 
ganglia of the autonomous nervous system, where noradrenaline is an essential 
regulator of cardiovascular tone and other functions in peripheral organs 108,109. In the 
brain, noradrenergic neurons are relatively few in number and concentrated primarily 
in the locus coeruleus (LC) in the pons, projecting widely to different regions of the 
brain, where it acts as an important modulator of cognitive functions, being an 
important target for the treatment of various psychiatric disorders 100,110,111. 
 
2.2.3 The serotonergic system 
Like noradrenaline, serotonin (also known as 5-hydroxytryptamine, 5-HT) was also 
initially identified due to its properties in peripheral organs, being first described as a 
vasoconstrictor by M. Rapport et al. in 1948 112. Later, serotonin was also found in the 
brain and shown to act as a neurotransmitter 113,114.  Serotonin is synthesized from L-
tryptophan in two steps by the enzymes tryptophan hydroxylase (TPH) and AADC, 
with TPH acting as the rate-limiting enzyme 95,115. In mammals, two isoforms of TPH 
have been characterized – TPH1, expressed primarily in peripheral organs, and TPH2, 
expressed primarily in the central nervous system 116,117. Like dopamine, serotonin is 
packed into vesicles by VMAT2 for release 96. Released serotonin can be removed 
from the synaptic cleft both by high-affinity transport by the serotonin transporter 
(SERT) and by a recently discovered low-affinity transport mechanism, mediated by 
PMAT 118. Degradation of serotonin in the brain is mostly mediated by isoform B of 
MAO 119. The serotonin receptors are highly heterogenous – seven different groups of 
receptors are known, with many of these displaying several subtypes 120,121.  
The vertebrate serotonergic neurons are located along the brainstem in several groups 
known as the Raphe nuclei, and send extensive projections to many brain regions 122. 
While involved in many brain functions, the serotonergic system has been of particular 
interest due to its involvement in depression, anxiety and other mood disorders, and 
substances modulating serotonergic neurotransmission have revolutionized treatment 





Figure 1. Overview of the synthesis of amine neurotransmitters. 
 
2.3 Histamine in the healthy and pathological brain 
 
In this chapter, key functions of the histaminergic system addressed and studied in this 
dissertation are reviewed. 
 
2.3.1 Histamine in the developing brain 
Although the functional relevance of histamine in brain development still remains 
poorly understood, histamine has been implicated as a regulator of neural 
differentiation. Histamine receptors HRH1, HRH2 and HRH3 are present in cultured 
cortical neural stem cells (NSCs) of the rat, and the expression of receptor mRNA is 
detected in many areas of the developing brain 126-129. Histamine was also found to 
stimulate proliferation, survival and differentiation of these NSCs, with HRH2 
signalling stimulating neural proliferation and HRH1 signalling steering the 
differentiation of NSCs into a neural direction 126. The functional relevance of this 
effect in vivo is not well understood.  Pharmacological inhibition of HRH1 signalling 
during rat development results in a smaller population of FOXP2-positive neurons in 
the developing cerebral cortex. The effect of this change on the morphology of the 
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adult brain was, however, not studied 130. Mice lacking histamine or histamine 
receptors have shown no gross morphological changes in the brain or phenotypes 
indicating severe neural dysfunction, suggesting that these effects on proliferation can 
be compensated by other signalling mechanisms 131,132. However, studies on the 
anatomy of different neural circuits in these mutant models are yet to be done.  In the 
zebrafish, knock-down of histamine synthesis and pharmacologic inhibition of Hrh1 
signalling during development results in impaired development of hypocretin-
expressing neurons 133. In the mice, HRH1 signalling was shown to inhibit 
development of dopaminergic neurons of the midbrain 134. These results further suggest 
that histamine might have relevance for the development of different neuronal 
populations in vivo, especially through HRH1 signalling. Elucidation of the role of the 
other histamine receptors in brain development would still merit further studies. 
 
2.3.2 Functional interactions between the histaminergic and other aminergic 
systems 
Studies on the histaminergic system have revealed that histamine regulates the function 
of all monoaminergic systems, acting largely through histamine receptor HRH3. 
Firstly, it was shown that histamine receptor HRH3 is located on the presynaptic 
terminals of monoaminergic neurons, with HRH3 signalling inhibiting the release of 
serotonin, noradrenaline and dopamine in the target areas of these neurons in different 
brain regions in rats and mice 78-81,135-137. Only the interactions with HRH3 and 
dopamine have been extensively studied further.  A recent study questioned this 
mechanism with regard to dopamine. In rat and mouse synaptosomes from nucleus 
accumbens, a part of the ventral striatum, it was discovered that HRH3 signalling 
inhibited dopamine synthesis through inhibition of cAMP synthesis, but HRH3 
signalling did not affect dopamine release 138.  In the striatum, HRH3 also has 
extensive postsynaptic interactions with dopaminergic circuits. GABAergic striatal 
medium spiny neurons, the main neuronal subtype in the striatum, express HRH3 
receptors that form dimers with dopamine receptors DRD1 and DRD2 and thus 
modulate their signalling 139,140. Activation of HRH3 counteracts both DRD1 and 
DRD2 mediated increases in locomotor activity in mice, while inhibition of HRH3 has 
the opposite effect 139. Functional HRH3 expression seems to also be necessary for 
dopaminergic signalling in the striatum, as mice lacking HRH3 have lower levels of 
DRD1 mRNA and show no phosphorylation of the extracellular signal-regulated kinase 
1/2, one of the secondary messengers of dopaminergic signalling 141. HRH3 also 
modulates striatal dopaminergic circuits indirectly, through inhibition of glutamatergic 
excitatory input from the cortex 142. Taken together, it is evident that HRH3 is an 
important mediator of monoaminergic, notably dopaminergic, signalling. There are 
also some studies implicating other histamine receptors in the regulation of 
dopaminergic circuits. HRH2 excites striatal medium spiny neurons, and HRH1 




2.3.3 Regulation of motor circuits by histamine 
Locomotion and other motor processes constitute one of the main functions of the 
central nervous system and make it possible for the organism to react to environmental 
cues and interact with the environment – thus, motor functions can be seen as the main 
expressive result of brain function. Histamine has been implicated in motor control in 
several brain levels. The vestibular nuclei in the brain stem, important centres in the 
control of posture and muscle tone, receive histaminergic innervation, and HRH2 
signalling facilitates motor functions of the lateral vestibular nucleus 144-147. The HRH1 
agonist / HRH3 antagonist betahistine has also been clinically used in the treatment of 
vestibular disorders 148,149. Histaminergic innervation is also prominent in the 
cerebellum, forming excitatory synapses with neurons in the cerebellar cortex and deep 
cerebellar nuclei 150. Injection of histamine into deep cerebellar nuclei enhances the 
performance of rats in several motor tasks 151,152. Additionally, both HRH1 and HRH3 
mRNAs are widely expressed in a majority of the nuclei of the thalamus, an important 
centre in the regulation of voluntary movement, although the precise role of histamine 
in the motor functions of the thalamus remains unknown 66,153. 
Studies in mutant mice also support a role of histamine in the regulation of motor 
functions. Mice lacking HDC, HRH1 or HRH3 receptor show reduced locomotor 
activity, and HRH1 knockout mice have reduced exploratory behaviour 154-158. 
However, it should be noted that histamine also strongly promotes wakefulness, and 
therefore these phenotypes may simply reflect a lower activity state of animals with 
genetically disturbed histamine signalling 90,159. HDC or histamine receptor knockout 
mice models have not shown impaired motor coordination 131,132. 
 
2.3.4 Histamine and the neurobiology of ethanol 
Ethanol is the most common substance of abuse, and ethanol addiction and overuse 
causes substantial morbidity and social issues worldwide. There is thus a great need to 
understand the neural circuitry and mechanisms underlying the neural effects of 
ethanol. The strong involvement of the dopaminergic network in the behavioural and 
reinforcing effects of ethanol administration has been well documented 160. Ethanol 
activates the neurons of the mesolimbic pathway, which leads to an increased release 
of dopamine in the nucleus accumbens, a key area in stimulant-induced locomotor 
activation 161-163. Dopamine receptor antagonists are able to inhibit ethanol-induced 
hyperactivity, further suggesting that dopaminergic pathways are essential in this 
response 164,165. The mesolimbic pathway, originating from neurons in the ventral 
tegmental area (VTA), is also essential in the development of substance addiction 166. It 
is thus evident that dopaminergic signalling is of pivotal relevance in the neurobiology 
of ethanol. However, the effects of ethanol in the brain are highly non-specific and not 
confined to one system. 
In animal models, addiction mechanisms are often studied using conditioned place 
preference (CPP), a setup in which an animal develops a preference for the 
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compartment in which it receives the addictive or rewarding substance 167. Several 
studies have shown that mice lacking histamine demonstrate stronger CPP by 
morphine and ethanol, which suggests that histamine would be relevant in the 
pathogenesis of addiction 168-170. Further studies into the mechanism behind this effect 
revealed that HRH3 antagonists inhibited ethanol-induced CPP and increased the 
release of histamine in the nucleus accumbens, suggesting that the mesolimbic 
dopaminergic pathway could be modulated by histamine at this site 171,172. The 
mechanism for this modulation is likely to be at least partially attributable to the 
dimerization of HRH3 with dopamine receptors in the striatum, as knockout of HRH3 
in mice results in impaired downstream signalling of DRD1 and DRD2 receptors in the 
striatum 141. Histamine has also been implicated as a mediator of the acute effects of 
ethanol, as mice lacking histamine show a decreased locomotor activation following 
ethanol administration 169. The mechanism by which histamine modulates acute effects 
of ethanol is still not completely understood. The HRH3 dimerization is likely to also 
modulate the dopamine signalling following the increased release of dopamine after an 
acute dose of ethanol. It is, however, important to also consider that the histaminergic 
system itself is affected by ethanol. In rats, acute ethanol treatment has been shown to 
increase histamine content and HDC activity in the hypothalamus, although the 
underlying mechanism has not been studied further 173. Thus, further studies into how 
the histaminergic system itself is affected by ethanol are warranted. 
 
2.3.5 Histaminergic signalling in the pathology of psychiatric conditions 
2.3.5.1 Tourette’s syndrome and autism spectrum disorders 
The pathogenetic processes behind psychiatric disorders are poorly and incompletely 
understood and generally involve changes in a multitude of neurotransmitter systems. 
However, even partial understanding of the involvement of individual 
neurotransmitters and neurotransmitter receptors in these conditions is of importance, 
as this could open up new avenues for development of better pharmacological 
therapies. Histamine has been implicated in several psychiatric diseases 174. Its 
involvement has probably best been described for Gilles de la Tourette’s syndrome, a 
condition characterized by involuntary repetitive motor behaviours called tics, after the 
discovery of a dominant mutant loss of function allele of HDC in a family with an 
autosomal dominant inheritance pattern of Tourette’s syndrome 175. A tic-like 
phenotype of repetitive behaviour was later reproduced in HDC knockout mice, which 
was reversible by injection of histamine into the brain, providing further evidence of 
the relevance of histamine signalling in Tourette’s syndrome 176. There is, however, no 
understanding of the mechanism by which histamine deficiency triggers Tourette’s 
syndrome. As the association between histamine and Tourette’s syndrome has so far 
been discovered in only one family, it is unlikely to explain most cases of Tourette’s 
syndrome. Interestingly, Tourette’s syndrome has substantial comorbidity with 
diseases of the autism spectrum disorder 177. These conditions are characterized by 
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impairments of social behaviour, communication deficits and repetitive, stereotypic 
behaviour 178. Some evidence suggests that histamine might also be relevant in autism 
spectrum disorders. Treatment with the HRH3 antagonist ciproxifan reversed the social 
behaviour impairment in a mouse model of autism, and a recent study found that 
patients with autism spectrum disorder had altered expression of genes in the 
histaminergic system, although this study was unable to identify which individual 
genes were affected in detail 179. These pioneer studies imply that histamine could 
regulate social behaviour, although further studies are necessary in order to understand 
the mechanism behind this. 
 
2.3.5.2 Anxiety disorders 
Early pharmacological studies demonstrated that HRH1 agonists increase, while HRH1 
antagonists reduce, anxiety-like light-avoidance behaviour in mice, suggesting that 
histamine acts as a modulator of anxiety 180,181. By contrast, HRH3 antagonists had an 
anxiogenic effect, which was attributed to inhibition of HRH3 autoreceptors on 
histaminergic terminals, resulting in increased histamine release and increased HRH1 
activation 181. Supporting this view, HRH3 agonists show anxiolytic effects in both rats 
and guinea pigs 182. In rats, the anxiogenic effect of histamine is at least in part 
mediated through histaminergic modulation of the amygdala, as histamine injected into 
the amygdala is anxiogenic, acting through a mechanism involving HRH1 but also 
DRD1 and DRD2 183,184.  
However, more recent studies in mutant mice have challenged the simplistic notion 
that histamine would be anxiogenic. Although HRH1 knockout mice display decreased 
anxiety-like behaviour in the elevated plus maze test, they do not show altered light-
avoidance behaviour in comparison to controls 185,186. HDC knockout mice that lack 
histamine completely show an increase in anxiety-like behaviour in several studies and 
test paradigms 158,187,188. An anxiogenic phenotype has also been observed after 
lowering brain histamine levels through limiting the availability of histidine in the food 
of mice 189. Knockout of HRH3 seems to have a complex effect on anxiety, increasing 
startle-induced anxiety responses but decreasing anxiety behaviour in the elevated plus 
maze 190. The discrepancy between results in mutant mice and pharmacological studies 
could imply that chronic inhibition of histamine signalling (i.e. mutant models) and 
acute inhibition (the current pharmacological studies) affect anxiety-like behaviour 
differently.  
 
2.3.5.3 Other psychiatric conditions 
Histamine has also been linked to several other psychiatric conditions. Patients with 
schizophrenia display decreased HRH1 and increased HRH3 radioligand binding in the 
frontal cortex 191,192. In a British study, a one amino acid substitution in the gene of 
HRH2 was found to be enriched in patients with schizophrenia, but this discovery was 
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not reproducible in other populations, thus casting doubts on its overall relevance 
193,194. Interestingly, HRH2 antagonists have shown some promise in the treatment of 
negative symptoms in schizophrenia. However, their beneficial effect may be transient 
due to the development of tolerance 195,196. Due to their pro-cognitive effects in 
preclinical trials, attempts have been made to use HRH3 antagonists for treatment of 
psychotic conditions 197. However, so far, clinical trials with HRH3 antagonists have 
not demonstrated efficacy in the treatment of schizophrenia 198. 
Patients suffering from depression have been shown to have lower levels of HRH1 
binding in the prefrontal cortex and gyrus cinguli in comparison to healthy controls, 
with the magnitude of this effect correlating with the severity of the symptoms 199. The 
HRH3 antagonist clobenpropit demonstrated antidepressant activity in a rat model of 
depression, and another HRH3 antagonist, pitolisant, was able to reverse depressive-
like symptoms caused by olanzapine in mice 200,201. However, the precise role of 
histamine in depression still remains unknown. 
 
2.4 The zebrafish as a model of the vertebrate brain 
 
2.4.1 Introduction of the zebrafish as a model organism 
The use of the zebrafish (Danio rerio) as a model organism was pioneered by Dr. 
George Streisinger at the University of Oregon almost 50 years ago. Streisinger’s goal 
was to find a vertebrate animal that could be used as a model for study of the genetics 
of the developing nervous system and be simple to maintain in a laboratory setting 202. 
The zebrafish had several properties making it a suitable candidate 202. Zebrafish breed 
readily all year round in a laboratory setting and several hundred embryos can be 
obtained from a single breeding, enabling experiments requiring a large number of 
individuals, such as drug screening setups 203. Zebrafish, like many other species of 
fish, are ovuliparous, and thus both the gametes and developing embryos are easily 
accessible to the researcher. This enables the use of several methods of genetic 
manipulation – indeed, the first major zebrafish paper from 1981 described the 
generation of homozygous diploid zebrafish embryos through conversion of haploid 
zebrafish eggs 204. In addition, zebrafish embryos are transparent until the end of 
organogenesis (achieved at 24 hours post fertilization, hpf), and the transparency can 
be retained even longer by treating the embryos with 1-phenyl 2-thiourea or by using 
zebrafish strains that are unable to produce pigment 205,206.  This has allowed for the 
development of non-invasive, light-based and high-resolution in vivo imaging 
techniques of different organ systems, which are virtually impossible to develop in 
other established vertebrate models in life sciences 207-209. Zebrafish embryos and 
larvae can easily be grown on a Petri dish and adult fish require considerably less space 
than a similar number of rodents 210. The easy accessibility of the developing zebrafish 
embryo has also facilitated the development of many different tools for genetic 
manipulation and gene function regulation 211-214. The zebrafish genome has also been 
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fully sequenced, which has made it possible to reliably identify the zebrafish 
orthologues of human genes 215. Taken together, these fundamental advantages of the 
zebrafish attracted greater interest and, eventually, led to general acceptance of this 
animal model in life sciences. 
 
2.4.2 Similarities and differences between the zebrafish and the mammalian brain 
Several fundamental principles of neurotransmission, such as the mechanism behind 
the action potential, have originally been discovered in organisms with quite simple 
neural networks 216. However, in order to model the function of neurotransmitter 
networks relevant to the mammal brain, these networks must be present in the model 
organism. At first glance, the morphology of the zebrafish brain appears quite different 
from its mammalian counterparts. The telencephalon in mammals contains many 
different regions that can be identified macroscopically, while the zebrafish 
telencephalon is much simpler and encompasses a much smaller fraction of the brain 
mass in comparison to mammals 217. However, although small in size, the zebrafish 
telencephalon contains regions homologous to mammalian structures, such as the 
amygdala, cortex and hippocampus 218,219. The fish also contain all major small 
molecule and amine neurotransmitter systems that have been described in mammals, 
and many of the neuropeptides are conserved as well 220. Additionally, important genes 
in brain development, such as the different classes of neurotrophic factors, have all 
been described in the zebrafish, suggesting that these developmental mechanisms are 
present and conserved also in the zebrafish 221-224. Although many of the systems are 
conserved, they still have some essential functional differences that will shortly be 
reviewed here for the systems addressed in this dissertation. 
 
2.4.2.1 The histaminergic system of the zebrafish 
The histaminergic neurons are localized in the posterior hypothalamus of the zebrafish 
and are first detectable by immunohistochemistry after 3 days post fertilization (dpf) 20. 
The histaminergic system in the zebrafish is highly similar to that of mammals, with 
histaminergic fibres projecting to many brain regions 225. The most notable difference 
is the absence of histamine fibre projections in the zebrafish cerebellum, while the 
mammalian cerebellum receives considerable histaminergic innervation (see chapter 
2.3.3) 20. Of the four mammalian histamine receptors, only the first three are found in 
the zebrafish. All of these are expressed in the brain of both larval and adult fish 226. 
Although the exact signalling properties of these receptors have not been published, 
they display considerable similarity to their mammalian isoforms – for instance, the 
domain responsible for the high constitutive activity of HRH3 is conserved 226. 
The peripheral tissues, including mast cells, are devoid of histamine in the zebrafish 
20,227. Thus, it would seem that biologically relevant histamine in the zebrafish is only 
synthesized by the hypothalamic neurons. This makes the zebrafish an optimal model 
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for study of the role of histaminergic neurotransmission, as there is evidence 
suggesting that mast cell derived histamine would also influence behaviour and interact 
with neural histamine receptors in mice 228,229. 
The metabolism of histamine in the zebrafish has not been thoroughly studied. 
Although the zebrafish has a homologue of HNMT that is expressed widely in the 
brain, nothing is known about its properties at the moment 230. Although low in 
mammalian brain, expression of DAO has been characterized in the zebrafish 
habenula, suggesting that oxidative deamination by DAO might partake in the 
metabolism of neural histamine in the zebrafish 231. 
 
2.4.2.2 The catecholaminergic systems of the zebrafish 
The dopaminergic system of the zebrafish is well developed and has been thoroughly 
characterized in several detailed studies 225,232-234. All dopaminergic populations that are 
found in the adult brain are present in the brain at 5 dpf, and the distribution of some of 
the cell groups are well conserved 225,233. The most notable difference between the 
zebrafish and mammals is the absence of dopaminergic neurons in the mesencephalon 
of the zebrafish, and it has thus been difficult to ascertain which of the populations is 
homologous with the mammalian substantia nigra 225. Current evidence implicates the 
diencephalic posterior tuberal dopaminergic population as the zebrafish equivalent of 
the substantia nigra 234,235. Other differences include a prominent population in the 
telencephalon and a pretectal diencephalic population, both of which are absent in 
mammals 225. 
The zebrafish has two isoforms of TH, named Th1 and Th2, which show a 
complementary expression pattern in the brain 232. In the brain, expression of th2 is 
confined to the hypothalamus and preoptic region of the diencephalon. Some cell 
populations express both th1 and th2 transcripts; the majority of only th2-expressing 
neurons are located in the posterior hypothalamus 236. This has allowed for the study of 
functions specific to the th2-expressing subset of dopaminergic neurons; these are 
currently known to be involved in the regulation of hypothalamic neurogenesis and 
initiation of locomotion 237,238. Differences in the transcriptional regulation of these two 
isoforms are still poorly understood. 
The noradrenergic neurons of the zebrafish are mainly located in the locus coeruleus in 
the hindbrain, with additional noradrenergic neurons being found in the medulla – this 
is highly similar to the noradrenergic system of mammals 225. 
Although poorly understood, notable differences in the metabolism of catecholamines 
exist between mammals and the zebrafish. The zebrafish has only one isoform of 
MAO, which seems to be primarily involved in the metabolism of serotonin, as 
inhibition of MAO has no effect on the concentrations of either dopamine or 
noradrenaline in the zebrafish 239. This suggests that catecholamines in the zebrafish 




2.4.2.3 The serotonergic system of the zebrafish 
Like the dopaminergic and histaminergic systems, all serotonergic populations of the 
zebrafish brain have developed by 5 dpf 233. The zebrafish has prominent serotonergic 
populations in the diencephalon, a feature common in other species of fish but not 
observed in mammals 225,240. The Raphe nuclei are conserved in the zebrafish and send 
extensive ascending and descending projections, as is the case in mammals 240. 
The zebrafish have three isoforms of tph – tph1a, tph1b and tph2 – all of which are 
expressed in the brain 241,242. Expression of tph1a is restricted to the diencephalic 
populations in the hypothalamus and tph2 is expressed in the raphe and pretectum 242. 
tph1b is expressed only transiently in development and its role is not well understood 
241. As mentioned above, serotonin is efficiently metabolized by MAO 239. 
 
2.4.3 Advantages and disadvantages of the zebrafish as a model organism 
 
2.4.3.1 The zebrafish genome duplication event 
In early evolution, many teleost species, such as the zebrafish, have undergone a 
genome duplication event 243. As a consequence, the zebrafish genome has two or 
several isoforms of many genes that are present only in one copy in mammals. This is 
the case for many genes relevant for neurotransmission, as reviewed in the previous 
chapter. As the isoforms often have an overlapping expression 232,244, it can be difficult 
to generate knockout models that completely lack the function of this gene. In some 
cases, however, the expression patterns of the two isoforms are complementary and 
restricted to specific regions of the organism, thus making it possible to study the effect 
of regional loss of function of a certain gene. Thus, the genome duplication has created 
both unique challenges and opportunities for using the zebrafish as a model. 
 
2.4.3.2 Analysing behaviour of the zebrafish 
Fruitful study of brain mechanisms usually requires a quantifiable readout. Different 
forms of behaviour are suitable readouts, as these can be monitored non-invasively and 
can also be used to model human symptoms, such as motor deficiencies and anxiety 
239,245. Zebrafish display a large repertoire of characteristic behaviours, many of which 
are already present in early larval stages 246. Basic locomotion can be easily studied in 
automated setups, giving high-throughput information about parameters such as 
locomotion activity and place preference of the fish 226,247. The small size of larvae 
allow for tracking of up to 96 individuals in the same trial, which makes it possible to 
track large numbers of individuals and several experimental groups in the same trial 
248. Additionally, the possibility to combine behavioural trials with non-invasive in vivo 
microscopy techniques has allowed for the detailed identification of cells and circuits 
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underlying specific forms of behavioural responses 249,250. These studies provide 
important information about the organization of neural circuits controlling behaviour at 
the cellular level, which is not feasibly obtainable in other established vertebrate 
models. 
The zebrafish is a diurnal species, and locomotion of zebrafish larvae is strongly 
regulated by the level of light and changes in illumination, and larvae display a 
preference for light 251,252. As light conditions can easily be controlled during 
experiments, the sensitivity of larvae to light has been utilized in several behavioural 
setups. For instance, the preference of light has been used to develop models of fear 
and anxiety in larvae 253. Rapid motor responses to sudden changes in illumination 
have been used to study the neural circuitry regulating alertness of the zebrafish 133. 
Several studies have also shown the zebrafish to be a suitable model for studying the 
mechanisms and pathology of sleep 254-256. However, it should be noted that sleep in 
zebrafish can only be defined by behavioural criteria, as it is not feasible to perform 
electroencephalographic recordings of the fish brain 252. 
Juvenile and adult zebrafish display a wide range of social behaviours, such as 
shoaling, social hierarchy between individuals and mating behaviour 246. Social 
behaviour can be analysed quantitatively using video recordings and algorithms that 
are able to track individual fish in a shoal 217,257. Zebrafish are thus a suitable model for 
elucidating the complex neurobiology of social behaviour, which is relevant in many 
human conditions such as autism spectrum disorder 258. However, not all fish social 
behaviours can be easily translated into corresponding human behaviours 217. For 
instance, there is no obvious equivalent of shoaling in mammals. There are also test 
paradigms available for other higher brain functions, such as memory and learning, 
although a detailed presentation of these methods is beyond the scope of this thesis 259. 
 
2.4.3.3 Whole-mount and live brain imaging techniques 
When studying the histological structure of the brain in rodents and other models, the 
brain often needs to be sectioned before analysis. The brain of the larval zebrafish is 
transparent, which has allowed for the development of histological methods using the 
whole brain as a sample. For instance, it is possible to do fluorescent 
immunohistochemistry and in situ hybridization on intact brains, although the limited 
availability of primary antibodies suitable for use in the zebrafish and the limited 
sensitivity of in situ hybridization methods can pose methodological challenges 234,236. 
It is thus possible to obtain information about the exact number of neural cell bodies in 
certain brain areas and visualize their projections, thus providing more detailed 
anatomical information about the relevant system than a mere study of histological 
sections 260. Using transgenic animals expressing fluorescent proteins in certain cells, 
different in vivo imaging setups have also been possible – for instance, activity of 
individual neurons can be imaged by expressing fluorescent calcium influx reporter 
genes 261. Although similar methods are available for other animal models as well, the 
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zebrafish is currently the most feasible vertebrate option for performing this imaging 
non-invasively, as the comparable setups in other animals (i.e. mammals) generally 
either require extensive surgical procedures or are limited to the imaging of superficial 
brain structures 262-264. 
 
2.4.3.4 Genetic manipulation methods 
The easy accessibility of zebrafish embryos has facilitated the development of many 
different techniques for gene function modification and genetic manipulation. Early 
studies focused mainly on forward genetic approaches, where male zebrafish are 
treated with the chemical mutagen N-ethyl-N-nitrosurea (ENU) to induce germline 
mutations. These fish are then crossed with wild type females and the offspring is 
subsequently screened for phenotypes 265. When a phenotype is found, the gene is then 
identified by cloning. This method was used in a large screen published in a single 
issue of the journal Development in 1996, in which many genes affecting the 
development of the zebrafish were identified 266. However, this method is extremely 
slow and requires large fish facilities for successful screens. 
One of the earliest reverse genetic methods utilized morpholino oligonucleotides that 
target specific RNA species to transiently inhibit the function of specific genes during 
development 267. However, morpholinos also have unspecific off-target effects, and not 
all morpholino phenotypes have been successfully reproduced when mutants of the 
same genes have become available 268. Together with the development of efficient 
techniques for reverse genetic screening, this has led to a decline in the use of 
morpholinos. The first widely used method to create constitutive knockout zebrafish of 
certain genes relied on the TILLING (Targeting Induced Local Lesions in Genomes) 
approach, in which the offspring of ENU-treated zebrafish are screened for mutations 
in the gene of interest 213. However, TILLING also results in numerous off-target 
mutations, which may affect the vitality and phenotype of the fish strain. Thus, a 
method for specific mutagenesis was needed. The pioneer method for creating 
mutations in specific genes of interest used zinc finger nucleases containing a DNA-
cleavage domain and a sequence specific DNA-binding domain to induce double-
strand breaks in the genome, resulting in mutations in the target site 269. Recently, 
however, the zinc finger nucleases have been virtually replaced in the zebrafish field 
by the CRISPR/Cas9 method, which has been adapted from a prokaryote immune 
defence mechanism against viruses. This method is based on synthesizing a small 
guide RNA, which targets a specific sequence in the genome, and Cas9 protein that 
cleaves both DNA strands at the binding site of the guide RNA 270. The endogenous 
repair of this double-strand break is error-prone, often causing deletions and thus 
resulting in a mutated gene. This method is specific and more efficient than previous 
methods of site-specific mutagenesis 271. More recent adaptations of the method have 
also made it possible to generate insertions using CRISPR/Cas9, opening up new 
avenues for overexpression studies and transgenics 272. 
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2.4.3.5 Ethical considerations in the use of zebrafish 
When using animal models, it is important to pay attention to ethical use of animals 
and animal welfare. Having a much less complex central nervous system, the zebrafish 
is generally considered to be a lower-ordered vertebrate than mammalian models such 
as the mouse and the rat 273. This motivates the use of zebrafish models instead of 
mammals, if a suitable zebrafish model is available. Additionally, many zebrafish 
studies can be carried out in larvae. According to the 3R guidelines, studies using 
immature forms of vertebrates are preferable to studies in adult individuals 274. 
Experiments done in larvae are also not subjected to legal regulation and do not require 
an animal experiment permit in the European Union, if the experiments are performed 
and the larvae are terminated before they start to feed independently (Directive 
2010/63/EU). By using larval zebrafish in pilot studies, for instance toxicity screens in 
drug development, it is also possible to reduce the number of mammalian animals 
needed in later stage experiments 275. However, for experiments involving adult fish, 
such as the generation of genetically modified fish strains, an animal experiment 
license is required, and the housing conditions, procedures requiring anaesthesia and 







Given the increasing pharmacological interest in the histaminergic system, a detailed 
understanding of the different aspects of the neuropharmacology of histamine is 
required. A better understanding of this transmitter system in relation to behaviour and 
other transmitter networks could lead to the discovery of new drug targets in the 
treatment of psychiatric and neurological conditions. However, in order to make proper 
hypotheses about possible treatment mechanisms involving the pharmacological 
modulation of histaminergic signalling, the basic functional properties of the system 
have to be thoroughly characterized. In this study, we aimed to answer some of the 
unresolved questions about the histaminergic system, using the zebrafish as a model of 
the vertebrate brain. 
The specific aims of this thesis project were as follows: 
 
1. Describe how the histaminergic system reacts to an acute dose of ethanol in 
comparison to the dopaminergic system. (I) 
 
2. Investigate factors regulating the expression of hdc. (I–III) 
 
3. Investigate the role of VMAT2 in histaminergic neurotransmission in comparison to 
other neurotransmitter systems. (II) 
 
4. Develop a fluorescent in situ hybridization protocol with sufficient sensitivity to co-
localize low-abundance transcripts in the zebrafish brain. (II–III) 
 
5. Identify the neurotransmitter phenotype of neurons expressing hrh3 in the zebrafish 
brain. (III) 
 
6. Characterize the effect of hrh3 knockout on behaviour, other transmitter networks 





4. Materials and Methods 
 
4.1 Experimental animals (I–III) 
Zebrafish from the wild-type Turku strain were used in all experiments. The mutant 
strain used in study III was also generated in the Turku strain, and thus shares a similar 
heritage. This strain was originally established from a mixed population of wild type 
zebrafish in Turku, Finland, and has since been maintained in our laboratory for almost 
two decades and used in several publications 20,133,225. The fish were maintained in a 
14/10 h light/dark cycle at a temperature of 27.5–28.5°C. Zebrafish embryos and larvae 
were raised in 1xE3 medium (5.00 mM NaCl, 0.44 mM CaCl2, 0.33 mM MgSO4 and 
0.17 mM KCl) until 8 dpf, when the larvae were transferred into tanks containing fish 
system water. 
Starting at 5 dpf, the fish were fed daily with SDS dry food (SDS Diets, Essex, United 
Kingdom), with the exception of fish used for experiments and terminated at 7 dpf. 
After reaching 14 dpf, fish were fed with SDS twice a day and additionally with 
artemia, which were grown from cysts according to the manufacturer’s instructions 
(Great Salt Lake Artemia Cysts, Sanders, USA). During weekends, fish were fed only 
once a day with artemia. Fish husbandry was based on the principles described by 
Westerfield 210. 
Larvae were killed in ice-cold water. Genotyping samples were collected by fin 
clipping under anesthesia with MS-222 (Sigma A5040, Sigma-Aldrich, MO, USA). 
Deformed and injured fish were not used in the experiments. All animal experiments 
were authorized by the Animal Experiment Board of the Regional State Administrative 
Agency of Southern Finland and the experiments were conducted in accordance with 
the EU Directive 2010/63/EU. All experiments were conducted in the Zebrafish unit of 
the Neuroscience Center of the University of Helsinki. 
 
4.2 Ethanol treatment (I) 
Absolute ethanol (>99.5%) was dissolved into 1xE3 to obtain treatment solutions 
containing 0.75, 1.50 and 3.00% of ethanol (Aa ethanol, Altia, Finland). The 
concentrations chosen were based on previous studies on ethanol in the zebrafish, and 
are similar to the internal concentrations measured in mice after acute administration of 
ethanol 277-279. 1xE3 without added ethanol was used for the control group. Treatment 
solutions were prepared fresh prior to the trial. 1 ml of solution was pipetted into each 
well of a 48-well plate. One 7 dpf larva was transferred to each well. The treatment 
durations used were 10 and 30 min. Samples of the larvae used in further experiments 





4.3 Reserpine treatment (II) 
The VMAT2 inhibitor reserpine (Sigma 83580, Sigma-Aldrich, MO, USA) was 
dissolved into 1xE3 at a concentration of 40 mg/L. Since reserpine is poorly soluble in 
water, the solution was vigorously agitated until no undissolved particles were seen 
and the solution appeared homogenous. Larvae were treated with reserpine at 4 dpf for 
either 20 min or 24 h. The 20 min treatment and the chosen reserpine concentration 
were based on a previous study, where adult zebrafish were treated with reserpine 280. 
The longer, 24 h treatment was included to evaluate the possible differences between a 
short and long reserpine treatment. During treatment, larvae were kept at a density of 
30 larvae / 3 ml treatment solution, and this density was also applied for larvae in the 
control group. After the treatment, the larvae were washed three times with 1xE3 and 
transferred to a clean plate. No difference in mortality was seen between controls and 
treated larvae. 
 
4.4 Behavioural tests (I–III) 
 
4.4.1 Locomotion effect of acute ethanol (I) 
7 dpf larvae were transferred to a 48-well plate, with each well containing 1 ml of 
ethanol solution (0% for controls, 0.75%, 1.50% or 3.00%). Group sizes were equal 
(12 larvae per group). After transferring the larvae to the plate, the locomotion 
behaviour of the larvae was tracked for 10 min using the EthoVision 3.1 software 
(Noldus, Wageningen, The Netherlands). The experiment was conducted under light 
conditions, with an illumination of approximately 330 lux in accordance with previous 
studies 133. In order to avoid light reflection artefacts in the tracks, the walls of the 
wells were coated manually with parafilm. The tracks were analysed by the software. 
Only tracks with no tracking artefacts and a detection rate over 90% were included in 
the analysis. Total distance moved, mean angular velocity, mean turn angle and mean 
meander for the trial were computed using a 0.2 mm minimum distance moved filter. 
The total distance moved was also analysed in 1 min bins. Larvae that did not move at 
all were considered abnormal and excluded from further analysis. The amount of 
excluded larvae per group was as follows: control 1/48, 0.75% ethanol 5/61, 1.50% 
ethanol 7/68 and 3.00% ethanol 2/55). 
 
4.4.2 Locomotion effect of reserpine treatment (II) 
The reserpine behavioural tests were conducted at 5 dpf and 7 dpf (24 h and 72 h after 
administering reserpine, respectively). 16 larvae per group were tracked on a 48-well 
plate, using the EthoVision XT 11.5 software and DanioVision DVOC-0040 tracking 
chamber (Noldus, Wageningen, The Netherlands). Before the trial, the larvae were 
habituated to the plate for 10 min. Basic locomotor activity in normal light conditions 
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was assessed for 15 min, followed by three periods consisting of 2 min of darkness and 
2 min of light. Illumination was set at approximately 330 lux, and light and dark 
transitions were instantaneous. A 0.2 mm minimum distance moved filter was used for 
the data analysis. The total distance moved and maximum distance moved per bout was 
analysed for the initial light period. For the altering light conditions, the distance 
moved was analysed in 1 min time bins. In order to analyse the dark-flash response, 
locomotion during the transition from light to dark was analysed in 1 sec bins. 
 
4.4.3 Locomotion of hrh3 mutant zebrafish (III) 
5 dpf wild type, heterozygous and knockout hrh3 larvae were tracked using the same 
DanioVision system as described in chapter 4.4.2. Total distance moved, mean turn 
angle, mean angular velocity and mean meander were analysed during a 15 min 
tracking period. Dark adaptation was analysed by tracking the larvae for 15 min in 1 
min bins after suddenly turning off the lights. 
 
Adult fish of each genotype were tracked in white, cylindrical containers using the 
EthoVision 3.1 system. In order to evaluate the place preference of the fish, the arena 
was divided into three virtual zones in the tracking software. The locomotion of the 
fish was tracked for 20 min in light conditions. The time spent in each of the zones and 
the same movement parameters as listed above for the larvae were analysed. 
 
4.4.4 Social behaviour of hrh3 mutant adult zebrafish (III, partially unpublished) 
6 adult fish were tracked as a group in the same white cylindrical container used in 
4.4.3. The fish were habituated to the arena for 5 min and tracked for 10 min. The 
individual fish swimming tracks were analysed using idTracker software, and the 
correlation of leadership scores and probabilities of the fish being in front were 
computed 257. The trial was repeated with four different groups of fish for each 
genotype. 
The shoaling behaviour of the hrh3-mutant fish was tested using a three-chamber setup 
developed by Dr. D. Baronio, which is similar to the setup used previously with 
rodents 281. A transparent square tank was divided into a rectangular compartment, with 
two equally sized smaller compartments facing its long side. One of the smaller 
compartments contained a shoal of fish and the other compartment contained stones. 
Shoaling preference was measured by counting the amount of time the fish spent in 
proximity to the tank containing the shoal of fish during a 10 min trial.  
Aggression was tested using the mirror test, where the fish were placed in a transparent 
rectangular tank with a mirror at one end 282. The time spent in proximity to the mirror 
during a 10 min trial was measured. A total of 12 fish of each genotype were analysed. 
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4.5 RNA extraction and cDNA synthesis (I–III) 
5–15 larvae were pooled into a microcentrifuge tube in order to obtain one RNA 
sample. Excess water was removed, and the sample was flash-frozen in liquid nitrogen 
or immediately processed through the RNA isolation protocol. RNA isolation was 
performed using the RNeasy Mini Kit (Qiagen, Hilden, Germany). In studies II and III, 
a DNase I treatment was included in order to verify the removal of all genomic DNA, 
as some of the PCR primers showed a strong tendency to amplify genomic DNA in 
pilot experiments of these studies. cDNA was synthesized using the SuperScript III 
reverse transcriptase kit (Invitrogen) using random hexamer primers in accordance 
with the kit protocol. In study I, 2 μg of RNA was used for the reverse transcription, in 
study II, 0.5–1 μg, and in study III 0.5 μg. The reason for using less RNA template is 
optimization of the qPCR to minimize the number of animals that needed to be pooled 
for one sample – we discovered during the years this project was carried out that 0.5 μg 
of RNA was sufficient for obtaining cDNA of a good quality. The cDNA was diluted 
10 times in nuclease-free water and this dilution was used as a template for qPCR. 
 
4.6 Quantitative PCR (I–III) 
In study I, quantitative PCR analysis was performed using the SmartCyclerII® 
(Cepheid) cycling platform. SYBR Green premix was obtained from Takara (Takara, 
Madison, WI, USA). The PCR reaction was set up according to the instructions of the 
cycler and premix kit. The reaction volume was 25 μl. Ct values were computed using 
the SmartCyclerII® software. 
In studies II and III, quantitative PCR was performed using the LightCycler® 480 
platform, with SYBR Green I Master reaction mixture produced by the platform 
manufacturer (Roche, Mannheim, Germany). All experiments were conducted using 
white 96-well plates. The reaction was set up according to the instructions of the 
manufacturer. Cp values (equivalents to the Ct value in other systems) were computed 
using the LightCycler® software. 
Relative expression of genes was calculated using the comparative C(T) method 
described by Livak and Schmittgen 283. In study I, beta actin (bactin) was chosen as the 
reference gene, as this gene has been reported to be the most stable reference gene in 
zebrafish exposed to chemical treatments and has also demonstrated good stability in 
other comparisons 284. In studies II and III, ribosomal protein L13 a (rpl13a) was used 
as a reference gene instead, because of a recent report that found it to be more stably 
expressed across different conditions 285. For the sequences of the primers used, please 





4.7 Antibodies (I–III) 
Please consult the table below for details of the antibodies used for 









1: 1000 Immunostar 22941 Kaslin and Panula 
2001 225 
 
Rabbit anti-histamine 1: 10000 Prof. Panula 19C Panula et al. 1990 15  
Rabbit anti-serotonin 1: 1000 Sigma S5545 Chen et al. 2012 221  
Alexa 488 goat anti-rabbit 1: 1000 Invitrogen A 11034 Sundvik et al. 2012 286  
Alexa 488 goat anti-mouse 1: 1000 Invitrogen A 11029 Sundvik et al. 2012 286  
Alexa 568 goat anti-rabbit 1: 1000 Invitrogen A 11036 Sundvik et al. 2012 286  
Alexa 568 goat-anti mouse 1: 1000 Invitrogen A 11031 Sundvik et al. 2012 286  
Sheep anti-digoxigenin-POD 1: 2000 Roche 11 207 733 910 Lauter et al. 2011 287  
Sheep anti-fluorescein-POD 1: 2000 Roche 11 426 346 910 Lauter et al. 2011 287  




4.8 Immunohistochemistry (I–III) 
Larvae were fixed in 4% paraformaldehyde (PFA) diluted in 1xPBS (phosphate 
buffered saline) overnight at +4°C. For histamine staining, the larvae were fixed with 
4% freshly prepared 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide in 0.1 M 
phosphate buffer pH 7.00.  
The next day, the larvae were washed for 3–4 hours in 1xPBS, after which the brains of 
the larvae were dissected under a stereomicroscope using #5 and #7 Dumont forceps 
(Fine Science Tools, Heidelberg, Germany). Brains were collected into meshed baskets 
kept on a 24-well plate, with each well containing 1 ml of PBS. All subsequent wash 
steps were carried out in the baskets on a 24-well plate.  
The brains were washed 3x30 min with PBS containing 0.3% Triton X-100 detergent 
(PBSTx) at room temperature (RT). After this, nonspecific binding sites were blocked 
by incubating the samples in PBSTx containing 4% normal goat serum (NGS, Gibco) 
and 1% dimethyl sulfoxide, overnight at +4°C. After blocking, the samples were 
incubated in primary antibody overnight for 16–24 h. The primary antibody was 
diluted in PBSTx containing 2% NGS. After incubation, the brains were washed in RT 
for 10 min and 3x30 min in PBSTx in order to remove excess antibody. The brains 
were then incubated at +4°C with Alexa fluorophore-conjugated secondary antibody 
diluted in PBSTx with 2% NGS. This was followed by a 10 min wash in PBSTx and 
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3x30 min washes in PBS, followed by 2x60 min incubations in 50% glycerol in PBS. 
Finally, the brains were incubated for at least 24 h in 80% glycerol in order for the 
tissue to be completely infiltrated and optimally cleared by the glycerol. The brains 
were then mounted between two 24 x 60 mm cover glasses, using 18 x 18 mm cover 
glasses to make a space between the larger glasses. 
 
4.9 Cloning of zebrafish vmat1 (II) 
A 735 bp fragment of the predicted zebrafish vmat1 (NCBI accession number 
XM_009304250.2) was amplified from cDNA obtained from whole zebrafish larvae. 
The primer sequences are reported in the original publication 289. The PCR reaction 
was set up using the DyNAzyme II kit (Thermo Scientific F-551), and the reaction was 
analysed on a 1% agarose gel. The band was excised from the gel and the DNA 
isolated with the Min Elute Gel Extraction kit (Qiagen, Hilden, Germany). In order to 
obtain a plasmid, the PCR fragment was subsequently ligated into the pGEM®-T easy 
vector (Promega A1360, Fitchburg, WI, USA). The plasmid was then transformed into 
competent DH5α E.coli bacteria. The successful cloning of the sequence was verified 
by sequencing the insert from both ends using T7 and SP6 primers.  
 
4.10 Riboprobe synthesis (I–III) 
All riboprobes used were synthesized from plasmids containing a fragment of the 
cDNA of the gene of interest as an insert, flanked by a RNA polymerase promoter 
sequence (T3, T7 or SP6). The plasmids were linearized with an appropriate restriction 
enzyme. 11-digoxigenin-UTP or 12-fluorescein-UTP labelled riboprobes were 
synthesized using 10x fluorescein or digoxigenin RNA labelling mix and an 
appropriate RNA polymerase (Roche, Mannheim, Germany), according to the 
manufacturer’s instructions.  
 
4.11 Chromogenic in situ hybridization (I–III) 
The hybridization procedure was based on the protocol by Thisse and Thisse 288. 
Larvae were fixed in 4% PFA diluted in 1xPBS and dissected as described in chapter 
4.7. The dissected brains were collected in methanol and stored at –20°C until used for 
in situ hybridization. 
During the in situ procedure, the brains were kept in 1.5 ml microcentrifuge tubes 
containing 1 ml of solution, unless otherwise noted. Brains were progressively 
dehydrated through a series of 5 min washes in 75%, 50% and 25% methanol diluted 
with 1xPBS containing 0.1% Tween-20 detergent (PBSTw). This was followed by 4x5 
min washes in PBSTw, after which the brains were permeabilized by treating them 
with proteinase K (1 μg/ml) for 10 min. The proteinase digestion was stopped by post-
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fixation with 4% PFA in 1xPBS for 20 min, followed by 4x5 min washes with PBSTw. 
Samples were then prehybridized in hybridization buffer (HB, 50% deionized 
formamide, 5x sodium salt citrate (SSC), 0.1% Tween-20, 50 μg/ml heparin, 500 
μg/ml tRNA with pH adjusted to 6.00 using citric acid) for 2 hrs at 65–67°C. 
Afterwards, HB was replaced with 250 μl HB containing 50–100 ng of digoxigenin-
labelled riboprobe. Hybridization was done overnight at 65–67°C for a minimum of 16 
h. 
Following hybridization, the samples were washed at 65–67°C as follows: briefly in 
HB, then 10 min each in 75%, 50% and 25% HB diluted with 2xSSCT (sodium salt 
citrate with 0.1% Tween-20), followed by a 10 min wash in 2xSSCT and two 30 min 
washes in 0.2xSSCT. HB used in these washes did not contain tRNA or heparin; SSCT 
buffers include 0.1% Tween-20. This was followed by 10 min washes in RT with 75%, 
50% and 25% 0.2xSSCT diluted with PBSTw and a final 10 min wash with PBSTw. 
The samples were blocked with PBSTw containing 2% normal sheep serum (NSS) and 
2 mg/ml bovine serum albumin (BSA) for 2 h in RT followed by incubation with Fab 
fragments of alkaline phosphatase conjugated sheep anti-digoxigenin antibodies, 
diluted to 1:7500 in blocking solution overnight at +4°C. 
On the last day of the protocol, excess antibody was washed away with at least 6 
washes in PBSTw, lasting on average 15 min per wash. Afterwards, samples were 
washed twice for 15 min in alkaline Tris buffer (100 mM Tris-HCl pH 9.5, 50 mM 
MgCl2, 100 mM NaCl, 0.1% Tween-20). The solution was thereafter replaced with 
staining solution, consisting of 225 mg/l nitro blue tetrazolium chloride (Roche, 
Mannheim, Germany) and 175 mg/l of 5-bromo-4-chloro 3-indolyl phosphate (Sigma-
Aldrich, MO, USA). Staining was monitored under a dissecting microscope. When a 
sufficient signal was seen, the reaction was terminated by several washes in 1xPBS. 
The samples were infiltrated with glycerol and mounted as described in chapter 4.7. 
 
4.12 Tyramide conjugate synthesis (II–III) 
Tyramides were synthesized following the protocol described by Hopman et al. 290. 
Succinimidyl esters of the following fluorophores were used in order to make 
respective tyramide conjugates: DyLight 488, DyLight 550, DyLight 633, DY-490, 
DY-560, DY-647P1, ATTO 488, ATTO 633, ATTO 647N, 5-(and-6)-
carboxyfluorescein (FAM), and 5-(and-6)-carboxytetramethylrhodamine (TAMRA). 
The tyramine solution was prepared by dissolving tyramine-HCl in dimethyl 
formamide at a concentration of 10 g/l (58 mM). The pH of the tyramine solution was 
adjusted to 7.00–8.00 by adding 10 μl/ml triethylamine into the solution. The 
succinimidyl esters were dissolved in anhydrous dimethyl formamide at a 
concentration of 10 g/l. The solutions were immediately mixed so that the molar ratio 
between ester and tyramine was 1.1. The reaction was allowed to proceed for 2 h at 
RT. The solution was then diluted to a final concentration of 1 mg/l with absolute 
ethanol, according to the mass of the unconjugated ester, and stored at –20°C. The 
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concentrations of tyramide used for the amplification reaction are indicated in the table 
below. 
Fluorophore Supplier of succinimidyl ester (product number) Dilution used for TSA 
DyLight 488 Thermo Fisher Scientific, Waltham, USA (46402) 1:250 (4 mg/l) 
DyLight 550 Thermo Fisher Scientific, Waltham, USA (62262) 1:250 (4 mg/l) 
DyLight 633 Thermo Fisher Scientific, Waltham, USA (46414) 1:167 (6 mg/l) 
DY-490 DyOmics, Jena, Germany (490-01) 1:250 (4 mg/l) 
DY-560 DyOmics, Jena, Germany (560-01) 1:250 (4 mg/l) 
DY-647P1 DyOmics, Jena, Germany (647P1-01) 1:250 (4 mg/l) 
Atto 488 ATTO-TEC, Siegen, Germany (AD 188-31) 1:250 (4 mg/l) 
Atto 633 ATTO-TEC, Siegen, Germany (AD 633-31) 1:250 (4 mg/l) 
Atto 647N ATTO-TEC, Siegen, Germany (AD 647N-31) 1:250 (4 mg/l) 
FAM Thermo Fisher Scientific, Waltham, USA (C1311) 1:250 (4 mg/l) 
TAMRA Thermo Fisher Scientific, Waltham, USA (C1171) 1:250 (4 mg/l) 
 
 
4.13 Fluorescent in situ hybridization (II–III, partially unpublished) 
The basis of the protocol for fluorescent in situ hybridization was adapted from Lauter 
et al. 291. The basic outline of the protocol is highly similar to the one described for 
chromogenic in situ hybridization in chapter 4.8. The differences between the protocols 
are briefly outlined here. 
Before rehydration, endogenous peroxidase was inactivated by incubating the samples 
for 20 min in 2% H2O2 in methanol. Hybridization was done at 60°C. The hybridization 
buffer contained 5% dextran sulphate but was otherwise identical to that used for 
chromogenic in situ. The post hybridization washes were performed at 60°C as 
follows: quick wash in HBW (50% deionized formamide, 2xSSC, 0.1% Tween-20), 
2x30 min in HBW, 1x15 min in 2xSSCT and 2x30 min in 0.2xSSCT. Thereafter the 
samples were washed 4x10 min in PBSTw, followed by blocking with PBSTw 
containing 8% NSS for 1–2 h in RT. Detection of the probe was performed using Fab 
fragments of peroxidase conjugated sheep anti-digoxigenin antibodies, diluted 1:500. 
After overnight incubation at +4°C, excess antibody was washed 6x15 min with 
PBSTw, followed by 2x15 min washes in TSA (tyramide signal amplification) buffer 
(0.1 M borate pH 8.5, 0.1% Tween-20). The probe was then detected by incubating the 
sample with tyramide reagent diluted in TSA working solution (0.45 g/l 4-iodophenol, 
2% dextran sulphate, 0.003% H2O2, 0.1% Tween-20) for 15 min. The reaction was 
stopped by four quick washes with PBSTw, where the tubes were vigorously shaken 
manually several times during each wash.  
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When two transcripts were detected in the samples (two-channel in situ), the 
peroxidase in the first antibody was now inactivated by incubating samples for 10–15 
min in 0.1 M glycine-HCl buffer, pH 2.00. To remove all glycine, samples were 
washed 4x5 min in PBSTw. The samples were then blocked and incubated with the 
second antibody as described above. The second riboprobe was labelled with 
fluorescein and detected using peroxidase-conjugated sheep anti-fluorescein 
antibodies, diluted at 1:500. After the final detection, the samples were washed 4x5 
min 1xPBSTw and then mounted in 75% glycerol containing 40 mM NaHCO3, in order 
to ensure a pH above 8 and optimal fluorophore performance. 
 
4.13.1 Optimizations tested for the fluorescent in situ protocol 
The protocol listed above resulted in sub-optimal detection results for low-abundance 
transcripts, such as hrh3. In order to optimize detection results and the signal-to-noise 
ratio, several optimizations to the protocol were tested. These have been previously 
described by King and Newmark for the planarian S. mediterrania 292. The following 
alternative protocols were tested: 
1. Replacing the proteinase K treatment with heat-induced antigen retrieval, performed 
by boiling the samples in 10 mM sodium citrate buffer pH 6.00, followed by 20 min 
incubation in PBSTw (no PFA postfixation). 
2. Using 0.3% Triton X-100 as a detergent instead of 0.1% Tween-20. 
3. Using a higher antibody dilution (1:2000 instead of 1:500) 
4. Investigating the difference between using higher (100 ng) and lower (50 ng) 
amounts of riboprobe. 
5. Using 100 mM NaN3 instead of glycine buffer for inactivation of the first peroxidase 
antibody. In order to completely remove NaN3, samples were washed 8x5 min with 
PBSTw after this step. 
6. Testing several different tyramide reagents. 
 
4.14 High-performance liquid chromatography (HPLC) (I–III) 
10–20 larvae were pooled per sample and flash-frozen in liquid nitrogen. The larvae 
were homogenized in 2% perchloric acid by sonication while keeping the samples on 
ice. The samples were then centrifuged for 30 min at 15 000 g. The supernatant was 
collected and 10 μl loaded as a sample for HPLC. Catecholamines, serotonin and their 
metabolites were measured using an electrochemical detector. The detailed procedure 
has been described earlier 234,239. Histamine was measured using a Shimadzu HPLC 
system equipped with a fluorescent detector setup according to the method described 
by Yamatodani 293.  The pellet was resuspended in 5% SDS and the protein 
concentration was measured using the Pierce™ BCA Protein Assay Kit (Thermo 
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Fisher Scientific 23227, Waltham, USA). The measured neurotransmitter amounts 
were normalized to the protein levels. 
 
4.15 Generation of a hrh3 knockout zebrafish (III) 
The hrh3 mutant line was generated using the CRISPR/Cas9 system 271. A 20 
nucleotide targeting sequence 5’-GGTGAGTGGAGACTGGGCAG was synthesized 
by annealing the oligonucleotides 5’-TAGGTGAGTGGAGACTGGGCAG and 5’-
AAACCTGCCCAGTCTCCACTCA. This sequence targets the second exon of the 
zebrafish hrh3 gene (NCBI Gene ID 561773). The targeting sequence was then cloned 
into the single-guide RNA expression vector pDR274 (Addgene plasmid #42250). The 
resulting construct was linearized by digestion with DraI and used as a template for 
single-guide RNA synthesis with the MAXIscript T7 kit. Cas9 mRNA was synthesized 
using the mMESSAGE T7 ULTRA kit, using a Cas9 expression plasmid (pMLM3613, 
Addgene plasmid #42251) linearized with PmeI as template. In order to induce the 
desired mutation, 26 pg single-guide RNA and 600 pg Cas9 mRNA were injected 
simultaneously into zebrafish embryos in the one-cell stage. The development of the 
injected embryos was observed, and normally developed embryos were analysed for 
mutations at the target site using T7 Endonuclease I assay and high-resolution melt 
curve analysis PCR (HRM-PCR, primers 5’-CGTACGTCCTGACGGGTG and 5’-
ACGCGGTGCACAACATATAATC). The target locus of potential founders was 
cloned into the pGEM®-T easy vector, as described in chapter 4.9. 
Three mutations were successfully identified. Out of these, a line with a 5 nucleotide 
deletion was chosen. This mutation results in a frameshift mutation and nonsense 
protein primary sequence after amino acid 133 and a premature stop codon at amino 
acid 312. The nonsense mutation causes a loss of 5 out of 7 transmembrane domains, 
the domain responsible for constitutive activity of hrh3 and the intracellular C-terminal 
domain. For a more detailed comparison of the sequences, please refer to the original 
publication (III). 
The fish were genotyped using the same HRM-PCR assay as described above. All 
comparisons between genotypes were performed using sibling fish. 
 
4.16 Microscopy and imaging (I–III) 
Light microscopy samples were analysed and imaged using a Leica DM IRB inverse 
bright-field microscope with an attached digital camera (Leica, Wetzlar, Germany). A 
whole-mount sample was imaged at several focal planes and a multifocus image was 
constructed using the Leica Application suite. Anatomical regions were identified 
according to Mueller and Wulliman 294. 
Fluorophore labelled samples were imaged using a Leica SP2 AOBS confocal 
microscope equipped with a 488 nm argon laser, a 561 nm diode laser and a 633 nm 
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helium/neon laser. Fluorophore emission ranges were set according to the technical 
details provided by the fluorophore manufacturer. They are described in more detail in 
the original publications. Cross-talk between channels was excluded by sequential 
scanning. For visualizing the entire brain, a HC PL APO 20x/0.70 CS objective was 
used. Higher magnification images for colocalization analysis were taken using HC PL 
APO 40x/0.75 CS and HCX PL APO CS 63x/1.3 GLYC objectives. 
Cell counting was performed manually from image stacks obtained by confocal 
microscopy using Fiji software, with the counter blinded to the sample type 295. 
Colocalization was determined from single optical sections. 
 
4.17 Statistical analyses (I–III) 
For all analyses, n was defined as an independent experimental unit. Analyses were in 
general conducted using 1-way analysis of variance (ANOVA), followed by Tukey’s 
post hoc test. The non-parametric Kruskal-Wallis test and Dunn’s post hoc test were 
used in cases where the variances were significantly different between groups, as 
determined by Bartlett’s test or the Brown-Forsythe test. In study I, the behavioural 
data was transformed with the function y=lg(y), in order to make the distribution 
normal and allow for the use of parametric tests. Values of 0 were substituted with 10-4 
in order to allow for the logarithm function to be used. 
Behavioural data analysed in time bins was analysed using 2-way repeated measures 
ANOVA followed by Tukey’s post hoc test (except in study I, where the Bonferroni 
post hoc test was used instead, as Tukey’s test was not available in the software at that 
time). 
The level of significance for all tests mentioned above was set at p < 0.05. All analyses 
were conducted in Graph Pad Prism version 5 (Study I) or 7 (Studies II–III) (Graph 







5.1 Acute ethanol affects locomotion in a biphasic, dose-dependent manner 
(I) 
Doses of 0.75% and 1.50% ethanol rapidly increased the locomotor activity of 7 dpf 
zebrafish larvae during the first 10 min following immersion in the treatment solution 
(Study I, Fig. 1a). This effect was significant for the 1.50% group (F(3,213) = 8.304 p 
< 0.0001). Interestingly, larvae treated with 3.00% ethanol seemed to have an equal 
swimming activity as controls. This was explained by a biphasic effect of 3.00% 
ethanol – analysis of locomotor activity in 1 min bins revealed that while the 3.00% 
groups initially showed a similar increase in locomotion as the 1.50% group, locomotor 
activity declined rapidly during the trial, and the 3.00% group showed significantly 
decreased locomotor activity in comparison to the control group during the last 5 min 
of the trial (treatment effect F(3,213) = 5.865 p = 0.0007; time effect F(9,1917) = 89.02 
p < 0.0001; Study I, Fig. 1e). This result suggests that higher doses of ethanol lead to 
sedation in zebrafish larvae. 
When analysing parameters describing the movement path of the larvae, we observed a 
significant increase in the mean angular velocity of larvae in the 1.50% group, in 
comparison to controls (F(3,213) = 16.18 p < 0.0001; Study I, Fig. 1c). We saw no 
biologically relevant changes in mean turn angle or meander, which implies that the 
increased angular velocity in the 1.50% group is due to a higher amount of turning 
behaviour rather than an increased magnitude of individual turns.  
 
5.2 Transcripts of enzymes synthesizing dopamine and histamine are 
rapidly upregulated by ethanol (I) 
After a 10 min ethanol treatment, mRNA transcripts of both rate-limiting enzymes of 
dopamine synthesis, th1 and th2, were upregulated in a dose-dependent fashion, with 
the 3.00% group showing a significant increase of both transcripts (th1: F(3,17) = 
3.439 p = 0.0405; th2: F(3,17) = 8.489 p = 0.0011; Study I, Fig. 2). A similar dose-
dependent increase was also observed for the histamine synthesizing enzyme hdc 
(F(3,17) = 5.515 p = 0.0079). 
 
5.3 Ethanol transiently decreases dopamine levels with no effect on 
histamine levels (I) 
A 10 min treatment with 3.00% ethanol significantly reduced dopamine levels by 
approximately 30% in zebrafish larvae (F(3,24) = 6.174 p = 0.0029; Study I, Fig. 7). 
The 1.50% group showed a similar decrease trend, while dopamine levels were 
unaltered in the 0.75% group. No significant differences were observed in the 
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concentrations of noradrenaline or the dopamine metabolites DOPAC and HVA across 
groups, although HVA levels appeared slightly lower in the ethanol-treated groups. As 
transcripts of th1 and th2 were upregulated at this same point in time, we hypothesized 
that this upregulation might reflect a compensatory response to the loss of dopamine. 
Thus, we analysed dopamine levels after a longer, 30 min treatment. At this point in 
time, no differences in dopamine levels were observed across groups. 
As for histamine levels, we found no significant change in any of the groups after a 10 
min treatment, although the histamine levels were slightly lowered in the 1.50% and 
3.00% groups. 
 
5.4 Unaltered morphology of histaminergic and dopaminergic networks 
after ethanol treatment (I) 
In order to investigate if the transcriptional changes reflected global or local changes in 
the dopaminergic and histaminergic systems, we analysed the distribution of th1, th2, 
and hdc mRNA in the brains of zebrafish larvae after a 10 min ethanol treatment. The 
expression patterns were unaltered between groups, suggesting that the transcriptional 
changes occurred in the same cells that express the mRNA species analysed under 
normal conditions. Th1- and histamine immunohistochemistry also showed unaltered 
cell population sizes, fibre projections and cellular morphology, supporting these 
conclusions (Study I, Fig. 3–4). As histological changes might become apparent on a 
longer time scale than molecular ones, we performed the same analyses using larvae 
treated with 1.50% ethanol for 30 min (Study I, Fig. 4 and 6). However, the longer 
treatment also showed no changes in the histaminergic and dopaminergic networks. 
 
5.5 Reserpine alters behavioural responses to sudden darkness (II) 
During normal light conditions, larvae treated with reserpine (both the 20 min and 24 h 
group) were hypoactive in comparison to controls (Study II, Fig. 2). The hypoactivity 
was more pronounced in the group treated for 24 h.  This effect was long-lasting and 
observed at both 24 h and 72 h after administration of reserpine (H(2) = 23.9 p < 
0.0001 and F(2,141) = 22.07 p < 0.0001, respectively). The maximum distance moved 
per bout of motor activity was unaltered or slightly increased in the reserpine-treated 
groups, suggesting that the neuromuscular pathways responsible for movement were 
intact. 
Zebrafish larvae increase their locomotion in response to sudden darkness in two 
phases 251. First, the larvae show a dark-induced flash response, a spike of locomotor 
activity during the first 500 ms of darkness. A 24 h reserpine treatment abolished the 
dark-flash response almost completely both at 24 h and 72 h after administration of 
reserpine, in comparison to controls (Tukey’s p < 0.0001 for all points in time, except 
in 3a where p = 0.0108; Study II, Fig. 3). The 20 min treated larvae showed 
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significantly decreased dark-flash responsiveness only at 72 h after administration of 
reserpine (Study II, Fig. 3d–f; Tukey’s p < 0.0001 except in 3d where p = 0.0339). The 
dark-flash response is of particular interest with regard to the study of the 
histaminergic system, as previous studies have demonstrated that decreased histamine 
levels inhibit this response 133,296. 
After the dark-flash response, zebrafish larvae show increased locomotor activity 
during the first several minutes following sudden onset of darkness, through a poorly 
understood neural mechanism 251. When analysing locomotor activity during 2 min 
periods of alternating light and darkness, we found that this response was significantly 
aggravated in both reserpine-treated groups 24 h after administration of reserpine 
(interaction effect F(22,1551) = 24.91 p < 0.0001; Study II, Fig. 2). When returning to 
light conditions, the reserpine treated larvae rapidly returned to baseline activity, being 
hypoactive in comparison to controls. At 72 h after administration of reserpine, both 
reserpine-treated and control larvae showed similar levels of locomotor activity.  
 
5.6 Neural histamine is depleted by reserpine (II) 
Immunohistochemical analysis revealed that histamine immunoreactivity in the brains 
of larvae was strongly decreased in both reserpine-treated groups at 72 h after 
administration of reserpine (Study II, Fig. 4). Importantly, immunoreactivity was 
almost completely absent in the fibre projections of the histaminergic neurons, 
suggesting that histamine was absent especially from the nerve terminals. The 
reserpine-treated larvae also showed a significantly decreased number of histamine 
immunoreactive neurons both at 24 h and 72 h after administration of reserpine, with a 
similar 40% decrease observed in both the 20 min and 24 h treated groups (F(2,35) = 
13.9 p < 0.0001 and F(2,43) = 26.34 p < 0.0001, respectively; Study II, Fig. 4). 
Although some neurons retained immunoreactivity in the soma, the projections of these 
cells did not show any detectable immunoreactivity. 
In order to verify that the decrease in histamine immunoreactive neurons was not due 
to reserpine toxicity, we analyzed the number of hdc mRNA positive neurons in the 
treated brains and found this to be the same as in controls. Thus, we concluded that the 
decrease in immunoreactivity reflects a decrease in histamine levels in the otherwise 
intact histamine neurons. 
As some of the histaminergic neurons retained immunoreactivity, we investigated 
whether the neurons were expressing different vesicular transporters. However, we saw 
that almost all hdc-positive neurons were also positive for vmat2 (Study II, Fig. 5). 
Additionally, we saw no expression of vmat1 mRNA in any region of the brain. This 
strongly suggests that vmat2 acts as the main vesicular transporter in all hdc-positive 
neurons, and the uneven depletion of histamine after reserpine treatment is due to a 




5.7 Depletion upregulates synthesis of monoamines but not histamine (II) 
As expected from studies in other vertebrates, reserpine strongly diminished levels of 
dopamine, noradrenaline and serotonin in the zebrafish (Study II, Fig. 7). The 
magnitude of the decrease was similar at both 24 h and 72 h after administration of 
reserpine. Dopamine (24h treatment: H(2) = 8.28 p  = 0.0062; 72h treatment: H(2) = 
9.42 p = 0.0024) and noradrenaline levels (24h treatment: H(2) = 10.22 p = 0.0006) 
were most sensitive to reserpine treatment, with both 20 min and 24 h treatments 
resulting in a 80–90% decrease of both transmitters. Serotonin levels were significantly 
decreased only by the 24 h treatment, while the 20 min treatment resulted in a 40–70% 
decrease that was not significant (H(2) = 10.21 p = 0.0007 and H(2) = 6.86 p = 0.0236 
for each point in time, rescpetively). Levels of histamine showed a similar sensitivity 
to reserpine as serotonin, with a significant 70–80% decrease observed only for the 24 
h group at both points in time (H(2) = 8.271 p = 0.0065 and H(2) = 12.5 p < 0.0001, 
respectively). 
In study I, decreased levels of dopamine were associated with increased th1 and th2 
transcripts, suggesting that depletion of dopamine upregulates this synthesis. Thus, we 
investigated whether reserpine-induced depletion of histamine and monoamines 
upregulated their synthesis by measuring relevant mRNA species by qPCR at 72 h 
after administration of reserpine (Study II, Fig. 6). We found that th1 (F(2,11) = 
9.F(2,11) = 9.515 p = 0.0040) and tph1a (F(2,11) = 4.552 p = 0.0363) were 
upregulated in the reserpine-treated groups, while th2 and tph2 were not, suggesting 
that these transcripts are differentially regulated by the depletion of their end product. 
Interestingly, dbh was extremely strongly upregulated, showing a 300% increase in the 
24 h treated group (F(2,11) = 29.98 p < 0.0001) and an increase trend in the 20 min 
treated group. In contrast to the other amines, histamine synthesis was not upregulated, 
showing an unchanged expression of hdc in the reserpine-treated groups. We also 
investigated if the monoamine reuptake mechanisms were upregulated. Only the 
noradrenaline transporter net was upregulated in the reserpine-treated groups (F(2,11) 
= 8.178 p = 0.0067), while the serotonin and dopamine transporters showed a similar 
level of expression as controls. We also saw no change in the expression of vmat2. As 
reserpine inhibits vmat2 irreversibly, this might in part explain why the effects of 
reserpine are extremely long lasting. 
 
5.8 Optimized fluorescent in situ hybridization protocol for detection of 
low-abundance mRNA species (II–III, development of protocol 
unpublished) 
Although many protocols for fluorescent in situ hybridization are available for the 
zebrafish, many of these have mainly been tested with genes that are expressed at a 
relatively high level, such as transcription factors that show abundant expression 
during development. However, transcripts with a lower level of expression, such as 
genes responsible for neurotransmitter synthesis and neurotransmitter receptors, are 
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more difficult to visualize, particularly when detecting two or more transcripts. Using 
the protocol described by Lauter et al. as a starting point, we performed several 
optimizations to develop a protocol that could be used to reliably detect transcripts 
with lower levels of expression. Firstly, we discovered that the tyramide signal 
amplification reaction produced less background when using a higher dilution of the 
peroxidase-conjugated antibody than recommended by the manufacturer (1:2000 
instead of 1:500).  
Secondly, we tested a large repertoire of different tyramide reagents (listed in chapter 
4.12). We found no better alternative for the red wavelength channel than the TAMRA 
conjugate described by Lauter et al. In the far-red channel, however, we found that the 
DY-647P1 tyramide worked much better than the previously described DyLight 633 
tyramide, showing a much clearer signal (Figure 2). In the green channel, the Atto488 
tyramide slightly outperformed the previously described FAM tyramide, showing 
better bleach resistance. Although both the Atto488 and DY-647P1 fluorophores have 
been available for some time, they had not been previously used successfully for 
whole-mount in situ hybridization. 
Whole-mount in situ hybridization in zebrafish has traditionally included a proteinase 
K treatment in order to permeabilize the tissue to the riboprobe. We tested an 
alternative permeabilization method described by King and Newmark for the planarian 
S. mediterrania, where the samples are permeabilized by boiling them in citrate buffer 
292. Surprisingly, we found that this heat-induced antigen retrieval method resulted in a 
greatly improved signal compared to the proteinase K treatment, allowing improved 
visualization of less abundant transcripts (Figure 3). We also found that, in accordance 
with King and Newmark, inactivating the first peroxidase-conjugated antibody using 
100 mM NaN3 instead of acidic glycine resulted in more consistent detection of the 
second riboprobe, although this improvement was less dramatic. We attempted 
replacement of the Tween-20 detergent with Triton X-100, as King and Newmark had 
discovered that this resulted in better detection. However, we noted that a change of 
detergent mostly increased background staining. 
Using these optimizations, we were able to reliably colocalize specific neural markers, 




Figure 2. Comparisons between different far-red tyramides. Note how the hrh3 signal in the 
dorsal telencephalon (outlined area) is far clearer when using the DY-647P1 tyramide in 
comparison to the DyLight 633 (DL633) tyramide. We also tested long-wavelength Atto 




Figure 3. Comparison between heat-induced antigen recovery in citrate buffer (method 2) and 
proteinase K treatment (method 1) for permeabilization. Note the stronger signal and more 
clearly identifiable cellular structures obtained by method 2. 
 
5.9 Expression of hrh3 in the zebrafish brain (III) 
hrh3 expression in the zebrafish has previously been poorly characterized, with 
previous reports showing moderate expression in the dorsal telencephalon 133. We 
discovered that the expression of hrh3 was much more widespread in the brain (Study 
III, Fig. 1). The strongest expression was consistently observed in the dorsal 
telencephalon (Study III, Fig. 1). However, we also saw prominent expression in the 
optic tectum, thalamic region and hypothalamus (Study III, Fig. 1). The hypothalamic 
expression was localized to the posterior hypothalamus, the region containing the 
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histaminergic neurons, and two bilaterally located populations in the anterior 
hypothalamus. 
During development, prominent hrh3 expression was firstly detected at 3 dpf (Study 
III, Fig. 1A–C). At this stage, prominent expression was seen in the pallium of the 
dorsal telencephalon, with weaker expression also seen in the posterior hypothalamus 
and the thalamic region. At 5 dpf, the anterior hypothalamic populations were 
detectable (Study III, Fig. 1F), and expression in the optic tectum became prominent at 
14 dpf (Study III, Fig. 1G–H). 30 dpf brains showed expression in the same regions as 
14 dpf brains (Study III, Fig. 1J–M). 
Although hrh3 expression has been characterized in several species, no direct 
histological evidence of the transmitter phenotype of neurons expressing hrh3 is 
available. Using our optimized fluorescent in situ hybridization protocol, we were able 
to identify the hrh3-positive cells of the pallium to be mostly glutamatergic, expressing 
the vesicular glutamate transporter vglut2.2 (Study III, Fig. 2A–C). The dorsal pallium 
also contains individual gad2 mRNA positive GABAergic neurons 297.  Interestingly, 
these neurons showed no hrh3 expression (Study III, Fig. 2D–F). Coexpression 
between hrh3 and gad2 was, however, seen in individual neurons in the ventral areas 
of the pallium (Study III, Fig. 2G–I). Our results thus indicate that the majority of the 
target neurons of hrh3 in the dorsal telencephalon are glutamatergic. We were further 
able to demonstrate that the zebrafish histaminergic neurons express hrh3, consistent 
with observations in other species (Study III, Fig. 2J–L). Due to the lower sensitivity of 
the fluorescent in situ protocol, we were unable to reliably identify the neurotransmitter 
phenotype of hrh3-expressing cells in other brain regions. 
 
5.10 hrh3 knockout larvae adapt faster to darkness (III) 
Using the CRISPR/Cas9 method, we successfully generated a hrh3 knockout strain of 
zebrafish (see chapter 4.15 and Study III, Fig. 3 for details). Larvae lacking hrh3 
displayed baseline-like locomotor activity at 5 dpf. Additionally, we saw no 
differences in parameters describing the swimming path of the larvae, such as meander 
and angular velocity. This indicates that the circuitry controlling basal movement 
coordination was intact in hrh3 knockout larvae (Study III, Fig. 4C–D, F–G). The hrh3 
knockout larvae also show a normal dark-flash response and showed a similar increase 
in locomotor activity upon sudden darkness as wild type and heterozygous siblings 
(Study III, Fig. 4A–B). However, we discovered that hrh3 larvae remained hyperactive 
for a shorter time after onset of sudden darkness, returning significantly faster toward 
baseline locomotor activity than wild type siblings (genotype effect F(2,91) = 3,259 p 
= 0.0430; Study III, Fig 4A). These results suggest that hrh3 can regulate adaptation of 
motor responses to sudden changes in the environment. 
We also analysed basic locomotion behaviour of adult zebrafish. We found that adult 
hrh3 knockout fish were significantly hypoactive in comparison to wild type siblings 
(F(2,27) = 4.23 p = 0.0252; Study III, Fig. 5A). We saw no differences in swimming-
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path parameters such as meander (Study III, Fig. 5B). A previous study found that 
depletion of histamine in adult zebrafish decreased the time spent in proximity to the 
edge of the tank, a characteristic behaviour known as thigmotaxis 247. We found that 
the time spent close to the edge of the tank was unaltered between hrh3 knockout fish 
and wild type siblings, suggesting that histamine does not regulate thigmotaxis through 
hrh3 (Study III, Fig 5C).  
As recent studies in rodents have implicated hrh3 in the regulation of social behaviour, 
we also analysed several metrics of social behaviour. We found that hrh3 knockout and 
wild type fish show a similar correlation between the leadership score of an individual 
and the probability of said individual to be swimming in front (Study III, Fig. 5D–F). 
Additionally, we have seen no differences in shoaling preference (t(18.99) = 1.584 p = 
0.1298) and aggressive behaviour (F(2,41) = 0.5261 p = 0.5948) between hrh3 
knockout and wild type fish (Puttonen et al, unpublished results, data not shown). This 
suggests that knockout of hrh3 does not significantly affect social behaviour of the 
zebrafish. 
 
5.11 Lower levels of serotonin and dopamine in hrh3 knockout larvae (III) 
A multitude of previous studies have shown that hrh3 regulates aminergic 
neurotransmission, as reviewed in chapter 2.1.5.4. However, these systems have not 
been previously described in hrh3 knockout animal models. We addressed this 
question using several methodological approaches. First, we analysed the expression of 
key genes in monoaminergic neurotransmission in all three genotypes using 
quantitative PCR. This included enzymes of monoamine synthesis (th1, th2, dbh, 
tph1a, tph2, ddc) and high-affinity monoamine transporters (dat, serta, sertb, net, 
vmat2). Additionally, we analysed the expression of hdc and the dopamine receptors 
(drd1, drd2a, drd2b, drd3, drd4b). We noted, however, that the expression of the genes 
mentioned above was completely unaffected by the hrh3 genotype. 
Next, we analysed the levels of monoamine transmitters by HPLC. We found that both 
dopamine and serotonin levels were significantly decreased in hrh3 knockout larvae 
(H(2) = 8.06 p = 0.0092 and F(2,13) = 3.948 p = 0.0457, respectively; Study III, Fig. 
6A, D). Levels of noradrenaline, adrenaline and the catecholamine and serotonin 
metabolites were not significantly altered across groups (Study III, Fig. 6B–C, E–G). 
In order to investigate whether the decreased transmitter levels resulted from 
structurally altered dopaminergic and serotonergic networks, we visualized these 
systems using Th1 and serotonin immunohistochemistry. We found that all Th1 and 
serotonin populations were identifiable in the brains of both hrh3 knockout and wild 
type larvae, and appeared to be of similar size (Study III, Fig. 7). The dopaminergic 
and serotonergic fibre projections also appeared intact. These results suggest that the 
decreased levels of serotonin and dopamine reflect functional changes in otherwise 
intact networks, and that hrh3 knockout does not significantly alter the development of 





6.1 Dopaminergic and histaminergic mechanisms in acute effects of ethanol 
(I) 
In this thesis, we discovered that a short, 10 min treatment with acute ethanol 
upregulated expression of rate-limiting genes in dopamine and histamine synthesis, 
th1, th2 and hdc. Dopaminergic mechanisms underlying acute effects of ethanol have 
been readily studied previously, and recently the histaminergic system has also 
attracted more attention in this field. However, previous studies have mainly focused 
on the neurochemical dynamics of these systems, with the molecular mechanisms 
having received considerably less attention.  
A few rodent studies have reported increased Th mRNA levels in the VTA following 
chronic ethanol treatment setups 298,299. Our results suggest that upregulation of th 
occurs rapidly after ethanol exposure, even in animals that have not previously 
encountered the substance. This is supported by the only mammalian study on the 
subject, where increased Th expression was observed in rats 1 h after administration of 
a single dose of ethanol 300. We already saw a significant increase after a 10 min 
treatment, suggesting an even more rapid transcriptional response than reported 
previously. Additionally, we found the magnitude of this upregulation to be dose-
dependent. Our in situ hybridization and immunohistochemistry results suggest that the 
transcriptional changes were not confined to any specific cell population, suggesting 
that the dopaminergic network was diffusely affected. This is also supported by the fact 
that both th isoforms were upregulated, as these isoforms are partly expressed in 
different brain regions – for instance, th2 is absent in the proposed zebrafish functional 
homolog of the mammalian mesencephalic dopaminergic groups 232,234. Although we 
analysed only transcript levels in this study, a later report proved that Th protein was 
increased by acute ethanol, supporting our results 301. 
We reported for the first time that acute ethanol upregulated hdc, following a similar 
dose-dependency as the upregulation of the th isoforms. In rats, increased histamine 
levels and histidine decarboxylase activity in the hypothalamus were reported in an 
early study 173. However, since the hypothalamus of rats also contains some mast cells, 
it was unclear whether these changes reflected alterations in mast cells or in neurons. 
In the zebrafish, however, hdc has been found solely in neurons 20. Thus, we present 
the first evidence of the upregulation of neuronal histamine synthesis after acute 
ethanol. As this upregulation is extremely rapid, it suggests that the histaminergic 
network itself is acutely modulated by ethanol and that the histaminergic system is not 
merely modulated by the other neurotransmitter systems. This is supported by the 
observation that histamine seems to be necessary for ethanol-induced hyperactivity in 
mice 169. In mice, acute ethanol does not alter histamine release in the nucleus 
accumbens, while dopamine release is increased in this region 171. However, ethanol-
related histaminergic dynamics in other brain regions has yet to be investigated. 
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Elevated brain histamine levels have been associated with alcohol preference in rats, 
and a single study has found increased levels of histamine in certain types of human 
alcoholics 302. Thus, the role of neural hdc in the pathophysiology of alcoholism should 
be further studied. 
The mechanism underlying the upregulation of histamine and dopamine synthesis is 
still unclear. We noted that dopamine levels in zebrafish larvae were decreased after a 
10 min ethanol treatment with the 1.50% and 3.00% doses. Ethanol is known to 
increase dopamine in other animals, and this depletion could be caused by a rapid 
increase in dopamine release. As the th isoforms were upregulated at this time, this 
would suggest a compensatory upregulation of synthesis in response to rapid dopamine 
depletion. This is supported by our observation that dopamine levels were equal across 
groups at 30 min after ethanol treatment. Additionally, this mechanism would explain 
the discrepancy between our results and previous studies in zebrafish that have 
consistently reported increased levels of dopamine following an acute dose of ethanol, 
as these studies have measured dopamine levels after a longer, 1 h treatment 303,304. The 
mechanism mediating the increase in transcription remains to be elucidated. A recent 
study showed that ethanol increases Th transcription in cultured midbrain 
dopaminergic neurons through the cAMP/PKA and MAPK/Erk kinase pathways 305. 
As the cAMP/PKA pathway is known to be an important downstream target of ethanol, 
it is also possible that th transcription is activated directly by ethanol, independently of 
dopamine depletion 306,307. It should, however, be noted that this effect was 
demonstrated by exposing the cells to a very high, 100 mM dose of ethanol, which 
cannot be considered physiological in mammals. Histamine levels were not 
significantly altered, and thus it seems unlikely that increased hdc transcription would 
be triggered by a compensatory mechanism. As the cAMP/PKA pathway stimulates 
histamine synthesis, the transcriptional effects of ethanol on hdc may also be related to 
this mechanism, although this needs to be studied further 25.  
As reported in previous studies, acute ethanol treatment increased locomotor activity of 
the larval zebrafish 277,278. We additionally demonstrated that higher ethanol doses had 
a biphasic effect on locomotion, showing an initial hyperactivity, which was rapidly 
followed by hypoactivity, similar to results in rodents 308. As these locomotor changes 
were associated with robust upregulation of both the dopaminergic and histaminergic 
systems, it suggests that these networks are involved in the locomotor response. Earlier 
studies have shown that both of these networks are relevant in the regulation of 
zebrafish locomotor activity. Both inhibition of hdc translation and pharmacological 
antagonism of histamine receptor signalling decreases locomotion of larval zebrafish 
133,226. As in mammals, amphetamine-induced dopamine release causes hyperactivity, 
and inhibition of dopamine signalling causes hypoactivity 280,309. Recently, it was 
shown that inhibition of Drd2 and tyrosine hydroxylase phosphorylation reduces 
alcohol-induced hyperactivity in the zebrafish 310,311. DRD2 inhibition also has a 
similar effect in mice, suggesting that the pathways mediating ethanol-induced 
hyperactivity are at least partially conserved 312. Thus, the dopaminergic mechanisms 
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may be more relevant to the observed locomotor response. The findings discussed here 
are summarized in Figure 4. 
 
Figure 4. Summary of currently known effects of acute ethanol on the histaminergic and 
dopaminergic systems in the zebrafish. Discoveries from Study I are indicated by a light-grey 
background. 
6.2 New aspects of the regulation of amine neurotransmitter synthesis (I–
III) 
One of the aims of this study was to identify factors regulating the expression of neural 
hdc. In addition to ethanol treatment, we examined the effect of depletion of neural 
histamine by reserpine and knockout of the hrh3 autoreceptor from the histaminergic 
neurons. This question is of relevance, as the alterations in brain histamine levels have 
been described in many different brain disorders, and transcriptional regulation of hdc 
is still poorly understood 58. 
Although reserpine-treated larvae showed decreased histamine levels, the expression of 
hdc was unaltered. Previous studies have shown that reserpine treatment in mice 
increases the activity of HDC, but the mechanism behind this has not been studied 35. 
Our results suggest that the underlying mechanism is likely to be related to post-
translational modification of HDC, rather than increased transcription. This is the case 
in the periodic regulation of HDC activity in the mouse brain, where Hdc mRNA levels 
remain stable but enzyme activities show diurnal fluctuation 313. 
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In contrast to the histaminergic system, reserpine treatment upregulated genes involved 
in the synthesis of other amine neurotransmitters. Interestingly, we only saw an 
increase in the expression of th1, while th2 remained unchanged. Previous studies in 
reserpinized rodents have also suggested that different dopaminergic populations react 
differently to dopamine depletion 314,315. For instance, expression in locus coeruleus is 
increased, while expression in the substantia nigra is not. The zebrafish th1 is 
expressed in the noradrenergic locus coeruleus and in the majority of the dopaminergic 
populations of the brain 232. Additionally, we found that the expression of dbh was 
greatly upregulated, suggesting that noradrenaline depletion results in a strong 
compensatory transcriptional response. Our results also suggest that it is unlikely that 
the increase in th1 and th2 mRNA expression following an acute dose of ethanol can 
be merely explained as a compensatory response to dopamine depletion, as the 
dopamine depletion observed after acute ethanol was much smaller in magnitude but 
still caused a much larger transcriptional response. Also, reserpine-induced dopamine 
depletion did not affect th2, while ethanol also upregulated the th2 transcript. 
We also observed a similar effect in serotonin synthesis – tph1a was upregulated, 
whereas tph2 was not. This is the first study to show differential upregulation of tph 
mRNA upon serotonin depletion in any species. This suggests that different serotonin 
populations show different transcriptional responses to serotonin depletion, as in the 
case of dopamine. This may have importance in understanding functional differences 
among serotonergic neurons, as recent studies have identified distinct subtypes of 
serotonergic neurons 316. 
In order to further understand transcriptional mechanisms in relation to monoamine 
depletion, we also analysed expression of the high-affinity monoamine transporters. 
We found, however, that only the noradrenaline transporter net was upregulated, 
whereas the serotonin and dopamine transporters were not. Together with the fact that 
dbh showed stronger upregulation than other rate-limiting enzymes, this suggests that 
noradrenaline depletion induces stronger compensatory transcriptional mechanisms 
than depletion of the other monoamines. This might reflect the importance of 
maintaining sufficient levels of noradrenaline, as knockout of noradrenaline synthesis 
is fatal in mice 317. 
We additionally investigated whether knockout of hrh3, the autoreceptor of 
histaminergic neurons, affected hdc transcription. However, hrh3 knockout zebrafish 
larvae showed normal expression of all enzymes of monoamine synthesis and all 
monoamine transporters, suggesting that removal of hrh3 does not affect monoamine 
synthesis at a transcriptional level. 
Taken together, we discovered that depletion of histamine does not induce 
compensatory changes in mRNA expression, while depletion of other aminergic 
neurotransmitters resulted in the upregulation of at least one synthesizing enzyme. 
These findings are summarized in Figure 5. Additionally, we described novel 
differences in the regulation of th and tph isoforms in the zebrafish, which is relevant 




Figure 5. Overview of changes in monoamine levels and related transcripts after reserpine 
treatment. Double arrows indicate a larger magnitude change. The histaminergic system is the 
only system not to show any transcriptional changes, while the strongest transcriptional changes 
occurred in the noradrenergic system. 
 
6.3 The role of VMAT2 in histamine storage (II) 
Although histamine transport by vmat2 has been described previously, its relevance to 
histamine neurons had not been previously characterized 31. We discovered that 
inhibition of vmat2 by reserpine treatment depleted almost all histamine 
immunoreactivity in axonal processes of these neurons. This implies that histamine 
was lacking especially in the axon terminals and in its site of action. Additionally, 
immunoreactivity in cell bodies was clearly decreased, although a subset of the 
neurons seemed to retain immunoreactivity. The decrease in histamine was verified 
independently by HPLC. Thus, we provide compelling evidence of the vmat2 
dependence of histaminergic neurotransmission. 
What could then explain the discrepancy in previous studies? Previous studies have 
relied on the use of HPLC measurements, which are unable to differentiate between 
neural and extraneural histamine 33-36. Maldonado and Maeyama tried to account for 
this by using rats lacking mast cells, and discovered that reserpine decreased histamine 
levels significantly only in rats with mast cells, which partially led the authors to 
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suggest that the neural pool of histamine would be relatively resistant to reserpine 35. 
However, if mast cell histamine constituted a significant amount of the histamine in the 
brain, basal histamine levels should be altered between the strains used, although the 
authors speculated that the lack of mast cell histamine might upregulate neural 
histamine synthesis by a poorly understood mechanism. Also, histamine synthesis is 
not restricted only to neurons and mast cells; for instance, neutrophils have recently 
been shown to produce histamine 318. Although we observed that histamine levels were 
less sensitive to reserpine treatment than catecholamine levels, our 
immunohistochemical results clearly demonstrate that the neural pool of histamine was 
significantly affected by reserpine. The differences between our studies could 
theoretically be related to differences in histamine metabolism between the zebrafish 
and mammals, but at least zebrafish mao shows a similar lack of histamine 
metabolizing activity as its mammalian counterparts 319. We therefore find it unlikely 
that the metabolism of histamine would be dramatically different in the zebrafish. 
One intriguing discovery was the retained immunoreactivity in a subset of histamine 
neuron soma. We did not discover the mechanism behind this. One possibility would 
be that a subset of histaminergic neurons expresses a different monoamine transporter. 
However, we concluded this to be unlikely, as virtually all hdc mRNA positive neurons 
in the zebrafish brain expressed vmat2, and we saw no expression of the other major 
monoamine transporter, vmat1 in the brain. This is consistent with observations in 
other species, showing that vmat1 is not significantly expressed in the brain 320. Thus, 
the reason for this observed heterogeneity remains to be elucidated. However, it is 
known that histaminergic neurons display heterogeneity in other properties as well. For 
instance, histamine neurons display differences in cotransmitter profiles and receptor 
expression 286,321. Thus, it is possible that differences in histamine synthesis or 
metabolism between individual histaminergic neurons could explain the uneven loss of 
histamine immunoreactivity, but this warrants further study. 
Recent reports have associated polymorphisms in the VMAT2 gene with the 
prevalence of several conditions, such as Parkinson’s disease, alcoholism, psychotic 
disorders and cognitive impairment after traumatic brain injury 322-326. As we have 
demonstrated conclusively the importance of VMAT2 in neural histamine storage, 
altered function of the histaminergic system should also be considered as a potential 
contributor to pathological processes involving VMAT2 polymorphisms. The 
relevance of altered VMAT2 expression to histaminergic neurotransmission should be 
further evaluated in different models, such as animals lacking or overexpressing 





6.4 Histamine and other monoamines as regulators of responses to sudden 
changes in the environment (II–III) 
The histaminergic system is known to be important in regulating the wakefulness of 
animals. For instance, periods of wakefulness in mice are correlated with histamine 
release, and HRH1 signalling has been shown to promote wakefulness 327-329. 
Importantly, HRH1 antagonists that cross the blood-brain barrier have substantial 
sedative effects in humans 330. In the zebrafish, histamine has been shown to regulate 
responsiveness to environmental cues. Burgess and Granato demonstrated that when 
illumination is suddenly turned off, zebrafish respond with an instantaneous burst of 
locomotor activity that lasts for approximately 500 ms 251. As this response results in a 
180° turn referred to as an O-bend, it has been suggested as having a navigational 
function, orienting the larvae back towards light upon suddenly entering a darker area 
251. The circuitry regulating the dark-flash response is still poorly understood. 
However, zebrafish with decreased neural histamine have an impaired dark-flash 
response. This effect has been shown both after inhibition of hdc translation by 
morpholinos and after inhibition of histamine synthesis by alpha-fluoromethylhistidine 
and also by inhibition of Hrh1 signalling 133. Additionally, presenilin 1 knockout 
zebrafish have a deficiency of histaminergic neurons and an inconsistent dark-flash 
response at 5 dpf, with unaltered morphology of other aminergic networks 296. Our 
observation of the lack of a dark-flash response in reserpine-treated animals might thus 
be explained by impaired histaminergic transmission, which further supports our 
conclusion that histamine transmission is vmat2 dependent. We also observed that the 
dark-flash response was more strongly impaired in larvae receiving a longer reserpine 
treatment. This also supports the importance of histamine in this response, as only the 
longer reserpine treatment significantly reduced histamine levels by HPLC. As hrh1 
and hrh3 are expressed partially in the same area of the dorsal telencephalon, we also 
investigated the dark-flash response of hrh3 knockout zebrafish larvae. This was 
unaltered, suggesting that the dark-flash response is not dependent on hrh3.  
A recent study described that hdc knockout zebrafish that completely lack histamine 
have an intact dark-flash response, leading the authors to suggest that the previously 
observed effect of impaired histaminergic transmission might be due to off-target 
effects of the used methods 248. It is true that morpholinos are notorious for off-target 
effects, and many – if not all – pharmacological substances also affect structures other 
than their intended target. However, the association between impaired histamine 
signalling and an impaired dark-flash response has been demonstrated with several 
methods – morpholino knockdown, three structurally different pharmacological 
compounds and a mutation impairing histamine neuron development 133,296. It is 
unlikely that all these methods would have the same off-target effect. Hence, other 
explanations for the lack of dark-flash impairment in hdc knockout zebrafish should be 
considered. It is known that complete knockout of a gene by a loss of function 
mutation may cause a different phenotype than partial knockdown of the gene or 
translation inhibition, for instance by triggering compensatory mechanisms 331. Further 
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studies, i.e. with inducible knockout models, should be conducted in order to 
conclusively settle the question of histamine as a regulator of the dark-flash response. 
After the dark-flash response, zebrafish larvae show transiently increased locomotion 
during adaptation to darkness, which slowly declines to a lower level of activity than 
during light conditions 251. This has been speculated as helping the animal move back 
into lighted environments 251. The circuitry regulating this behaviour is not known. We 
discovered that depletion of amine neurotransmitters increased this hyperactivity. 
However, the exact aminergic network responsible remains to be determined. 
Histamine is unlikely to be involved, as histamine-depleted animals do not display a 
similar phenotype. Monoaminergic networks innervated the nucleus of the medial 
longitudinal fasciculus in the zebrafish midbrain, a region necessary for the control of 
swimming velocity, and monoamine depletion could thus affect the swimming speed of 
larvae 332. The dopaminergic and serotonergic networks in particular also project 
extensively to many other regions regulating motor activity, such as the subpallium in 
the telencephalon (homologous to the mammalian basal ganglia) and the motor 
neurons in the spinal cord 235,333. Thus, the regulation of locomotion by monoamines 
occurs on several different levels, and extensive studies will still be necessary to 
precisely dissect the mechanism by which monoamines regulate hyperactivity after 
sudden darkness. We were, however, able to contribute one additional piece to this 
puzzle, as we discovered that the adaptation of this hyperactivity was faster in hrh3 
knockout larvae. This suggests that hrh3 can regulate adaptation to sudden changes in 
the environment. 
The hyperactivity occurring after darkness has also been suggested as representing 
anxiety-like behaviour and stress caused by a sudden change in the environment 
334,335.Thus, the increased dark-induced hyperactivity observed in the reserpine-treated 
larvae could suggest increased anxiety-like behaviour. This would be consistent with 
previous observations in vmat2 heterozygous fish, which show increased anxiety-like 
behaviour in a dark avoidance test 336. The observation that hrh3 knockout larvae adapt 
faster to this stimulus could further be interpreted to suggest that hrh3 could be 
involved in the regulation of adaption to anxiogenic stimuli in the zebrafish. However, 
there was no change in thigmotaxis, the preference for the outer rim of a tank, in adult 
hrh3 knockout zebrafish (discussed in detail in chapter 6.5). As thigmotaxis is a more 
established measure of anxiety, it seems unlikely that the faster adaptation to darkness 
observed in larvae would represent altered anxiety. Also, hrh3 knockout larvae showed 
a wild type-like initial hyperactivity, with only the adaptation being altered. Anxiolytic 
treatments have been shown not to affect the habituation of zebrafish to the 
environment 337. Thus, we find it unlikely that the faster adaptation to darkness is 
related to anxiety.  
How, then, does hrh3 regulate the circuitry relevant to adaptation to darkness? We saw 
very strong hrh3 expression in the pallium of the zebrafish. This region contains the 
areas of the zebrafish brain that are functionally equivalent to the mammalian cortex, 
amygdala and hippocampus, which are important centers in the regulation of behaviour 
219. We discovered that hrh3 was expressed predominantly in glutamatergic neurons of 
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the pallium. In the zebrafish, neurons from the pallium send extensive projections to 
lower brain regions, and knockout of hrh3 could alter the function of these neurons 133. 
However, we also detected hrh3 expression in the optic tectum of the zebrafish. This 
region is involved in the regulation of visually elicited motor responses, and it is thus 
also possible that hrh3 alters the adaptation to darkness at this site as well 249.   
Regardless of how hrh3 knockout alters adaptation to darkness, our results imply that 
hrh3 regulates the glutamatergic component in the pallial projection neurons, but we 
do not know with certainty whether Hrh3 protein is localized postsynaptically in the 
cell bodies or presynaptically in the axon terminals. The HRH3 radioligand binding 
profile in the zebrafish brain does not show significant binding in the pallium, 
suggesting that a presynaptic location of HRH3 in the axon terminals of these neurons 
is more plausible 338. Interestingly, hrh1 is also prominently expressed in the pallium, 
and this area receives dense histaminergic innervation 133. Thus, it is possible that 
histamine could modulate the pallial neurons bidirectionally – exciting them at the cell 
body and dendrites through hrh1, and inhibiting them at the axon terminal through 
hrh3. A diagram of this theoretical circuit is outlined in Figure 6. It would be relevant 
to study this potential mechanism further in mammals, as it could reveal a complex 
regulatory role of histamine in the function of cortical projection neurons. Although 
both HRH1 and HRH3 are expressed in the mammalian cortex, their precise location in 
the cortical circuits remains unknown 67. 
 
 
Figure 6. A hypothetical schematic of how histamine receptors could regulate glutamatergic 
neurons in the dorsal telencephalon. Ascending inputs from the hypothalamic histamine neurons 
(HA) synapse with the glutamatergic target neurons with Hrh1, which send projections to other 
brain areas. The axon terminals of the glutamatergic neurons express Hrh3, which regulates 
transmitter release at these terminals. Projections of neurons are based on earlier studies 133. 
 
6.5 The zebrafish hrh3 knockout phenotype (III) 
Aside from the faster adaptation to darkness described in the previous chapter, hrh3 
knockout had a minimal effect on the behaviour of zebrafish. Adult hrh3 knockout fish 
were hypoactive in comparison to controls, but otherwise displayed similar locomotor 
coordination. This is consistent with studies in mice 154,231. However, larval zebrafish 
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displayed completely normal basal locomotion, suggesting a different role of hrh3 in 
the locomotor activity of larval and adult zebrafish. This is in contrast to previous 
results showing that Hrh3 antagonists cause hypoactivity in larval zebrafish 226. 
However, this study also reported a similar effect of Hrh3 agonists. Agonists and 
antagonists of a receptor are unlikely to have the same effect on the animal, and thus it 
is likely that these pharmacological effects are at least partially explained by 
nonspecific effects of the compounds. However, the exact binding profile and receptor 
affinity of these ligands in the zebrafish have not been properly characterized. 
Differences in HRH3 ligand affinities and effects between species have been 
previously described between the human and rat isoform of HRH3 339. 
Previous studies have shown histamine and HRH3 to be involved in anxiogenic 
responses in mice, but this association has remained enigmatic, as described in chapter 
2.3.5.2. Histamine has also been suggested as being involved in anxiety in the 
zebrafish. In adult zebrafish, depletion of histamine increases the time fish spend 
swimming in the center of the tank (and thus decreases thigmotaxis), which has been 
interpreted to suggest decreased anxiety-like behaviour 133. An opposite phenotype is 
seen in psen1 knockout fish, which, as adults, have an increased number of 
histaminergic neurons 296. We did not find any differences in the place preference of 
hrh3 knockout adult fish, suggesting that this response is not mediated by hrh3. In 
order to better understand the involvement of hrh3 in anxiety, the behavioural response 
to different anxiogenic conditions and drugs should be evaluated in this model. 
Additionally, we investigated different metrics of social behaviour in adult hrh3 
knockouts, but found these to be similar to controls. Thus, although hrh3 inhibitors 
may have beneficial effects on social behaviour in disease states such as autism 281, it 
seems that it has a minimal role in regulating social behaviour in the normal brain. 
Interestingly, we discovered that hrh3 knockout larvae had lower levels of dopamine 
and serotonin than wild type siblings. This effect was not due to an altered morphology 
of the dopaminergic or serotonergic networks or to altered transcription of enzymes of 
monoamine synthesis and transport, as all these measures were unchanged between 
genotypes. This is the first study to characterize monoaminergic systems in hrh3 
knockout animals in detail. Altered transmitter levels in otherwise intact networks 
suggest that the function of these networks is changed. The mechanism for this remains 
to be elucidated. However, altered levels of dopamine and serotonin could be of 
relevance in the observed faster adaptation to darkness. For instance, dopamine is an 
important regulator of locomotor circuits in the zebrafish, while serotonin regulates 
light-seeking behaviour in zebrafish larvae 340-342. 
In conclusion, the zebrafish hrh3 mutant displays minimal phenotypes. However, the 
altered habituation to darkness and decreased dopamine and serotonin levels in hrh3 
knockout zebrafish larvae motivate further studies using this model to better 
understand how hrh3 knockout affects the function of the brain. As the zebrafish larva 
is an exceptionally versatile model for in vivo imaging techniques, these could be 




6.6 Evaluation of applied methodology (I–III) 
The use of zebrafish larvae for these studies minimizes uncontrolled genetic and 
environmental variation between the animals and experimental groups. Larval 
zebrafish can easily be raised in standardized conditions on a Petri dish. In our mutant 
studies, all comparisons were made between siblings, removing the risk of maintaining 
separate homozygous lines that could have unidentified genetic variation acquired 
throughout the generations. Thus, the error arising from differences between subjects 
should be minimal. However, it should be noted that zebrafish strains display a larger 
genetic variability than inbred rodent strains, which is partially due to a relatively 
strong inbreeding depression in zebrafish 343. Although one study has shown 
preliminary evidence that it might be possible to create inbred zebrafish strains in the 
future, these strains have yet to be firmly established in the zebrafish research 
community 344,345. Therefore, regardless of the experimental setup, zebrafish studies 
have an inherently larger interindividual genetic variation than mice. It should also be 
noted that our studies were conducted using a wild type strain that is specific to our 
animal facility. However, this Turku strain has been used in many publications for over 
20 years 20,133,296,297,319,338,346.  
Although the need to pool larvae in order to obtain sufficient samples for qPCR and 
HPLC results in a need for a larger number of animals, this also increases the reliability 
of the sample, as the measured value will represent a mean of several individuals. 
However, the small size of the larvae makes it unfeasible to dissect brains from unfixed 
larvae, and thus, our results may partly be affected by changes in peripheral organs. As 
vmat2 and hrh3 in the zebrafish are both predominantly expressed in the brain, it is 
unlikely that genetic or pharmacological manipulation of these proteins would result in 
predominant changes in the periphery 226,347. Also, histamine and monoamine levels are 
clearly higher in the brain than in peripheral organs of larvae 237. Thus, the error 
introduced into the results by peripheral effects should be minimal. 
Our fluorescent in situ hybridization protocol allowed for reliable demonstration of 
coexpression of transcripts, and should also be useful for this purpose in future studies. 
Of particular interest is the ability to detect transcripts of low abundance, such as 
GPCR mRNAs. However, as this method still shows less sensitivity than the 
chromogenic in situ hybridization protocol, some regions may be difficult to analyse 
reliably. In the case of hrh3, we were not able to properly evaluate the coexpression of 
hrh3 with all relevant markers, such as genes responsible for monoamine synthesis. In 
our experience, the major obstacle is the significant loss of sensitivity when detecting 
the second riboprobe. Additionally, in situ hybridization is unable to provide 
information about where in the cell the protein synthesized from the mRNA species is 
expressed. This would be most properly evaluated by immunohistochemistry, although 
this method is unfortunately unavailable for many proteins of interest due to the lack of 
reliable antibodies that work with the zebrafish (although this issue is prominent in 
most other model organisms as well). The antibodies used in this dissertation have all 
been thoroughly characterized in previous publications. 
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As discussed when evaluating the discrepancy in results between comparable 
knockout, knockdown and pharmacological manipulations, knocking out a gene 
function completely might lead to compensatory mechanisms in the organism that 
mask part of the loss of function. Thus, certain normally hrh3-dependent mechanisms 
may still be intact in our knockout model. For instance, lack of this receptor may 
change the way synapses where this receptor normally is present form during brain 
development, and thus alter the brain circuitry. The only feasible way to avoid this 
situation is the creation of inducible knockout lines, where a protein function can be 






In this dissertation, I aimed to uncover novel mechanisms in the function of the 
histaminergic system. Our main conclusions were as follows: 
 
1. Ethanol rapidly upregulates expression of neural hdc in a similar manner as th1 and 
th2 are upregulated. Acute ethanol treatment caused a rapid decrease in dopamine 
levels, which recovered during a longer treatment, suggesting that the upregulation of 
the th mRNA species is a compensatory mechanism. Histamine levels, however, 
showed no significant changes after ethanol treatment. These results suggest that 
ethanol rapidly modulates the histaminergic and dopaminergic systems at a 
transcriptional level. Additionally, ethanol stimulates locomotor behaviour of larval 
zebrafish, with higher doses being sedative after longer exposure. This is similar to 
observations in mammals. The rapid changes in the dopaminergic and histaminergic 
systems occurred in the same time frame as the locomotor activation, suggesting that 
these networks are likely to be involved in locomotor responses to ethanol in the 
zebrafish. 
 
2. Inhibition of VMAT2 by reserpine strongly diminished histamine immunoreactivity 
from both neural soma and axonal projections and decreased total histamine levels. 
Other monoamine levels were also decreased. However, whereas decreases in other 
monoamine levels upregulated their synthesis, hdc expression was not changed, 
implying that histamine depletion does not trigger a compensatory upregulation of hdc. 
Additionally, we saw that the histamine-mediated dark-flash response was impaired in 
reserpinized zebrafish larvae, suggesting that histaminergic transmission was impaired. 
 
3. The optimized protocol for fluorescent in situ hybridization with sufficient 
sensitivity to detect transcripts with low-moderate expression developed in this study 
was sensitive enough to detect low-level mRNAs. Using this method, we identified 
most of the hrh3-expressing neurons in the dorsal telencephalon to be glutamatergic, 
while hrh3 was also detected in individual GABAergic neurons in more ventral regions 
of the telencephalon. Additionally, we saw expression of hrh3 in hdc mRNA positive 
neurons. 
 
4. The new zebrafish model with a loss-of-function allele of hrh3 was phenotyped in 
this study. The hrh3 knockout larvae showed a faster habituation to sudden darkness, 
which suggests a role of hrh3 in the adaptation and regulation of responses to sudden 
changes in the environment. Adult hrh3 knockout fish were hypoactive, while larvae 
showed normal locomotor activity, suggesting a different role of hrh3 in regulation of 
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locomotion in different developmental stages. Social behaviour was unaffected by hrh3 
knockout. hrh3 knockout did also not affect the development of aminergic networks or 
the expression of key genes in monoaminergic neurotransmission. However, dopamine 





8. Questions for Future Research 
 
1. The acute histaminergic responses to ethanol still need to be evaluated further, 
particularly as regards how ethanol affects the activity of hdc. As we discovered that 
ethanol upregulates hdc, it would also be of interest to study possible alcoholism-
related polymorphisms in the human hdc promoter, to see if this mechanism has 
clinical significance. 
 
2. The role of VMAT2 in the function of histaminergic neurons needs to be studied 
further in models lacking and overexpressing VMAT2 in the histamine neurons 
specifically. This could reveal how VMAT2 affects histamine turnover and 
metabolism, which could be relevant when considering the pathogenetic mechanisms 
related to VMAT2 polymorphisms. 
 
3. Differences in histamine metabolism and turnover among histaminergic neurons 
should be investigated. This could most robustly be done by single-cell sequencing of 
the transcriptome of these neurons. 
 
4. Inducible knockout models of histamine receptors and hdc should be generated, in 
order to see how removal of specific components of the histaminergic system in a 
normally developed brain affects behaviour and other parameters. Additionally, the 
changes in brain activity patterns under different conditions caused by histamine 
receptor and hdc knockout (both inducible and classic ones) should be characterized. 
 
5. In order to better understand the partially contradictory results obtained with our 
Hrh3 knockout fish and Hrh3 ligands, the properties of zebrafish histamine receptors 
need to be characterized using in vitro expression of the receptors in cells, and the 
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